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(57) ABSTRACT 
Halogenated phenylethynyl-substituted heterocycles that 
possess either an N-alkylamino or N,N-dialkylamino group 
attached to the heterocycle or halogenated phenylethynyl-
substituted benzenes that a nitrogen-containing heterocycle 
attached to the benzene inhibit the proliferation cancer cells 
and are useful antineoplastic agents. 
20 Claims, 2 Drawing Sheets 
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1 
PHENYLETHYNYL-SUBSTITUTED 
BENZENES AND HETEROCYCLES FOR THE 
TREATMENT OF CANCER 
2 
one or more of the halogenated phenylethynyl-substituted 
heterocycles or pharmaceutical compositions thereof. 
One aspect of the present disclosure is directed to halo-
genated phenylethynyl-substituted benzenes or heterocycles 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims the benefit of U.S. Provisional 
Application No. 62/523,081 filed 21 Jun. 2017 and the 
benefit of U.S. Provisional Application No. 62/636,463 filed 
28 Feb. 2018, the entire disclosures of each of which are 
hereby incorporated by reference herein. 
5 that are useful for killing hyperproliferating cells such as 
cancer cells for the treatment of human malignant and 
benign cancers, including without limitation, colorectal can-
cer (CRC), leukemias, breast cancer, ovarian cancer, lung 
cancer, prostate cancer, and liver cancer. In this aspect of the 
10 disclosure, there are provided certain halogenated phenyl-
ethynyl-substituted heterocycles having anti-neoplastic 
activity against cancerous cells. The halogenated phenyl-
ethynyl-substituted benzenes and heterocycles of the present 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
15 
disclosure include compounds according to formulas (I), (II) 
and (III): 
This work was supported by NIH grant numbers ROI 
CAI 72379 and P30 GM110787 and was also supported by 
the Office of the Assistant Secretary of Defense for Health 20 
Affairs, through the Prostate Cancer Research Program 
under Award No. W81XWH-16-l-0635. The government 
has certain rights in the subject technology. 
TECHNICAL FIELD 25 
The present disclosure relates to compounds that treat 
cancer and/or treat or prevent cancer metastasis. In particu-
lar, the subject technology is directed to halogenated phe-
nylethynyl-substituted benzenes bearing nitrogen-contain- 30 
ing heterocycles attached to the benzene and directed to 
halogenated phenylethynyl-substituted nitrogen-containing 
heterocycles, their salts and their pharmaceutical composi-
tions and methods for treating cancer therewith. 
35 
BACKGROUND 
A family of fluorinated N,N-dialkylaminostilbene analogs 
that inhibit the expression of Wnt target genes, such as 
c-myc, and repress colon cancer cell growth in vitro and in 40 
vivo was reported. See, e.g., J Med Chem 2011, 54:1288-
1297; ACS Chem Biol 2013, 8(4):796-803; J Med Chem 
2014, 57:6083-91; U.S. Pat. No. 8,664,276. 
In addition, certain diarylacetylenes are known for certain 
medicinal uses. See, e.g., WO2012149049; 45 
WO2012149048; WO2010092043; WO2009038759; 
WO2008073350; and WO2001029011. Further, U.S. Pat. 
No. 8,716,355 to Tsai discloses hydroxylated tolans and 
related compounds in the treatment of cancer and Hadfield 
et al. disclose preparation and evaluation of diarylalkynes as 50 
antitumor agents. Hadfield et al., Synth Commun. 1998, 
28(8): 1421-1431. 
Halogenated diarylacetylenes and methods for treating 
cancer have also been reported. See U.S. patent application 
publication number 2015-0272908; Sviripa, et al. "Haloge- 55 
nated diarylacetylenes repress c-myc expression in cancer 
cells", Bioorg Med Chem Lett 2014, 24:3638-40. 
However, there is an ongoing need for additional com-
pounds that can be used to treat cancer and other ailments. 
(I) 
Ys 
(II) 
(III) 
Ys 
or a pharmaceutically acceptable salt thereof, wherein 
each of X 1 through X5 independently represents H, lower 
alkyl, alkoxy, e.g., lower alkoxy, halo, and/or NR1R2 , 
wherein each of R1 and R2 independently represents H, or a 
lower alkyl, n is either 1 or O and when n is 1, each ofY1 
through Y4 independently represents H, a lower alkyl or 
alkoxy, or NR1 R2 . Heterocycle represents a heterocycle ring 
that can be unsubstituted or substituted with one or more 
lower alkyl or alkoxy, e.g., lower alkoxy groups, and/or one 
or more halogens; wherein the heterocycle is selected among 
oxopiperidine, morpholine, piperazine, N-methylpiperazine, 
N-pyrrole, and 2,5-dimethyl-N-pyrrole, quinoline, isoquino-
line, indole, indazole, naphthyridine, and pyridinyl; and Y5 
represents one or more NR1 R2 , and/or one or more halogens 
which can be the same or different. 
The halogenated phenylethynyl-substituted benzenes or 
SUMMARY OF THE DISCLOSURE 
60 heterocycles of formulas (I), (II), or (III) or pharmaceuti-
cally acceptable salts thereof can be included in a pharma-
ceutical composition with a pharmaceutically acceptable 
earner. Advantages of the present disclosure include halogenated 
phenylethynyl-substituted benzenes or heterocycles and 
pharmaceutical compositions thereof which have antine- 65 
oplastic activity and methods of inhibiting cancer cell 
growth and/or treating cancer in a patient by administering 
Another aspect of the present disclosure is directed to 
methods of treating cancer, e.g., inhibiting cancer cell 
growth and/or inhibiting tumor growth in a mammal, such as 
a human, or treating diseases associated with hyperprolif-
US 10,449,186 B2 
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erating cells. In one embodiment of this aspect of the 
disclosure, an effective amount of one or more halogenated 
phenylethynyl-substituted benzenes or heterocycles, phar-
maceutical salts and/or pharmaceutical compositions thereof 
is administered to a patient in need of treatment of cancer 5 
sufficient to treat/inhibit cancer cell growth in the patient. 
In an embodiment of this aspect of the disclosure, a 
therapeutically effective amount of one or more halogenated 
phenylethynyl-substituted benzenes and heterocycles, phar-
maceutical salts and/or pharmaceutical compositions thereof 10 
is administered to a patient suffering from colorectal cancer. 
In another embodiment, a therapeutically effective amount 
of one or more halogenated phenylethynyl-substituted ben-
zenes bearing nitrogen-containing heterocycles attached to 
the benzene and one or more halogenated nitrogen-contain- 15 
ing phenylethynyl-substituted heterocycles, pharmaceutical 
salts and/or pharmaceutical compositions thereof is admin-
istered to a patient suffering from liver cancer or prostate 
cancer. 
Additional advantages of the present invention will 20 
become readily apparent to those skilled in this art from the 
following detailed description, wherein only the preferred 
embodiment of the invention is shown and described, simply 
by way of illustration of the best mode contemplated of 
carrying out the invention. As will be realized, the invention 25 
is capable of other and different embodiments, and its 
several details are capable of modifications in various obvi-
ous respects, all without departing from the invention. 
Accordingly, the drawings and description are to be regarded 
as illustrative in nature, and not as restrictive. 30 
BRIEF DESCRIPTION OF THE DRAWINGS 
4 
nyl-substituted benzenes and heterocycles, a pharmaceutical 
salt thereof, or a pharmaceutical composition thereof. It was 
found that halogenated phenylethynyl-substituted benzenes 
and heterocycles having at least one, preferably two, halo 
substituents in one aryl ring and an amine in the opposing 
aryl or heteroaryl ring, e.g., N-methylamino or N,N-dim-
ethylarnino, inhibit the proliferation of LSI 74T colon cancer 
cells through the inhibition of c-myc and induction of the 
cyclin-dependent kinase inhibitor-I (i.e., p21 Wifl!Cipl). Such 
compounds and compositions are useful as antineoplastic 
agents. 
The halogenated phenylethynyl-substituted benzenes and 
heterocycles of the present disclosure include at least one 
amine group, e.g., a primary, secondary or tertiary amine, on 
the benzene or in the heterocycle ring of the halogenated 
phenylethynyl-substituted benzenes and heterocycles. Such 
compounds are useful as antineoplastic agents and can be 
represented by the following formula: 
(I) 
or a pharmaceutically acceptable salt thereof. The sub-
stituents of X1 through X5 each independently represent H, 
a lower alkyl or alkoxy, e.g., lower alkoxy, halo, and/or Reference is made to the attached drawings, wherein 
elements having the same reference numeral designations 
represent similar elements throughout and wherein: 
FIG. 1 shows the structural formula for 2,6-difluoro-4'-
(N,N-dimethylamino )stilbene (1) and 2,6-difluorophenyl-4'-
(N,N-dimethylamino )phenylacetylene (2). FIG. 1 also illus-
trates a synthesis for heterocyclic-substituted phenylethynyl 
benzenes 4 and phenylethynyl-substituted heterocycles 5 
and 7. Legend: a, heterocyclic-substituted phenyl iodide, 
iPr2EtN, Pd(PPh3 ) 4 , Cul, H2 0, 80° C.; b, heteroaryl iodide, 
iPr2EtN, Pd(PPh3 ) 4 , Cul, H20, 80° C.; c, chloro-substituted 
heteroaryl iodide, iPr2 EtN, Pd(PPh3 ) 4 , Cul, H20, 75° C. 
followed by mono- or dialkylamine, THF, 130° C., 2-3 h, 
pressure tube; d, fluorinated heteroaryl iodide, iPr2EtN, 
Pd(PPh3 ) 4 , Cul, H20, 80° C. 
35 NR1 R2 , wherein each ofR1 and R2 independently represents 
H, or a lower alkyl. In an embodiment of the present 
disclosure at least one of X1 through X5 is a halo and the 
remaining X1 through X5 represent H, a lower alkyl or lower 
alkoxy. In another embodiment of the present disclosure at 
40 
least ofX1 through X5 is NR1R2 . A halo group means an F, 
Cl, Br, or I. Preferably substituents X1 through X5 include at 
least two halo groups, e.g., F and/or Cl. In an embodiment 
of the present disclosure, X1 and X5 are halo groups such as 
45 two F groups, two Cl groups or an F and Cl group. 
FIG. 2A is a western blot showing the effects of 4-((2,6-
difluorophenyl)ethynyl)-N,N-dimethylaniline (2), 4-((2,6- 50 
difluoropheny l)ethyny 1)-N,N-dimethy lisoquinolin-1-amine 
(5nn), and 4-((2,6-difluorophenyl)ethynyl)-N-methylisoqui-
nolin-1-amine (500) on the expression of cyclin Dl and 
p21 Wifl!Cipl in LSI 74T cells at 300 nM concentrations. 
FIG. 2B is a plot of dose responses of compounds 2, 5nn 55 
and 500 in a LSI 74T cell proliferation assay. IC50 values for 
2, 5nn and 500 were 25.1±1.3, 11.8±1.5 and 4.2±0.2 nM, 
respectively. 
DETAILED DESCRIPTION OF THE 
DISCLOSURE 
60 
The present disclosure relates to halogenated phenylethy-
nyl-substituted benzenes and heterocycles, their salts and 
their pharmaceutical compositions and methods of inhibit- 65 
ing cancer cell growth and/or treating cancer in a patient by 
administering one or more of the halogenated phenylethy-
The variable n can be 1 or 0. When n is 1, the halogenated 
phenylethynyl-substituted benzenes of formula (I) can be 
represented by formula (II) below. 
(II) 
Ys 
For formula (II), each of Y1 through Y4 independently 
represents H, a lower alkyl, or NR1R2 , wherein each of R1 
and R2 independently represents H, or a lower alkyl. 
When n is 0, formula (I) can be represented by the 
halogenated phenylethynyl-substituted heterocycles of for-
mula (III) below. 
US 10,449,186 B2 
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(III) 
6 
more of compounds according to formulas (I), (II), or (III), 
or a pharmaceutically acceptable salt of a compound of 
formulas (I), (II), or (III). 
In one aspect of the present disclosure, the compounds of 
Ys 
5 formula (I), (II) or (III), a pharmaceutically acceptable salt 
thereof, or a pharmaceutically acceptable composition 
thereof is used in the treatment of cancer. The method 
comprises administering to a patient in need of such treat-
ment an effective amount of one or more of the halogenated 
10 phenylethynyl-substituted heterocycles, a pharmaceutical 
salt thereof, or a pharmaceutical composition thereof. 
Embodiments of the method include wherein the cancer 
treated is selected from among colorectal cancer, leukemias, 
The substituents of X1 through X5 for formula (II) and 
(III) are as described for formula (I) including all combina-
tions thereof. For each of formulas (I), (II) and (III), Het-
erocycle represents a heterocyclic ring. For example, Het-
erocycle represents a heterocycle ring that can be selected 15 
from among oxopiperidine, morpholine, piperazine, 
N-methylpiperazine, N-pyrrole, and 2,5-dimethyl-N-pyr-
role, quinoline, isoquinoline, indole, indazole, naphthyridine 
and pyridinyl. For each of formulas (I), (II) and (III), the 
heterocycle ring can be unsubstituted or substituted with one 20 
or more lower alkyl or alkoxy, e.g., lower alkoxy groups, 
and/or one or more halogens. The variable Y5 in each of 
formulas (I), (II), and (III) represents one or more NR1 R2 , 
and/or one or more halogens which can be the same or 
25 
different, that is each NR1 R2 group can have the same or 
different R1 and R2 , wherein each of R1 and R2 indepen-
dently represents H, or a lower alkyl, and/or the Heterocycle 
can have one or more of the same or different halogen. In an 
embodiment of the present disclosure, Y 5 in each formulas 30 
(I), (II), and (III) represents one or more NR1R2 . In another 
embodiment of the present disclosure, Y5 in each of formu-
las (I), (II), and (III) represents one or more halogens. For 
example, for formula (III), at least one ofX1 through X5 is 
NR1 R2 and Heterocycle represents a pyridinyl ring having at 35 
least one halogen and preferably two halogen groups, e.g. 
fluoro and/or chloro groups. 
The term "lower alkyl" includes saturated aliphatic 
groups, including straight-chain alkyl groups, branched-
chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl sub- 40 
stituted cycloalkyl groups, and cycloalkyl substituted alkyl 
groups having from one to about ten carbons (C1 -C10), e.g., 
from one to about six carbon atoms (C1 -C6 ) in its backbone 
structure. In one aspect of the present disclosure, the lower 
alkyl groups specifically include methyl, ethyl, propyl, iso- 45 
propyl, n-butyl, etc. 
breast cancer, ovarian cancer, lung cancer, prostate cancer 
and liver cancer. 
In the course of studies focused on the mechanisms of 
colorectal cancers, we employed chemical biology to probe 
cell signaling events that regulate gene expression. Selective 
targeting of key steps in this process offered the potential for 
developing therapeutic agents to treat these cancers. We 
reported, for example, that the 2',6'-dihalostyrylanilines (1) 
(FIG. 1) inhibited the expression of Wnt target genes, such 
as c-myc, and repressed colon cancer LSI 74T cell growth in 
vitro and in vivo. See, e.g., J Med Chem 2011, 54:1288-
1297; ACS Chem Biol 2013, 8(4):796-803; J Med Chem 
2014, 57, 6083-91. We established that this agent targeted 
exclusively the catalytic subunit of the oligomeric enzyme, 
methionine S-adenosyltranferase-2 (MAT2) that furnishes 
S-adenosylmethionine (SAM) to regulatory methyltrans-
ferases and that is upregulated in a selected group of cancers. 
We further established that heterocyclic variants of these 
2',6'-dihalostyrylanilines (1) possessed minimal gross tox-
icity, no human ether-a-go-go-related protein (hERG) acti-
vation as desired, reasonable bioavailability and pharma-
cokinetics. As desired, these stilbene-based agents did not 
affect methionine S-adenosyltransferase-1 (MAT!) that 
served as the principal source of SAM necessary for other 
cellular needs. Unlike a recent report of other MAT2A 
inhibitors, we also demonstrated in vivo potency in a xeno-
graft model using colorectal cancer cells. 
Concerns regarding thermal or photochemical EZ-isomer-
izations in stilbenes 1 that could potentially complicate 
future pharmacokinetic and pharmacodynamic studies led to 
synthesis and evaluation of the analogous diarylacetylenes 2 
(FIG. 1). In accord with the SAR study of the stilbenes 1, we 
found that the diarylacetylenes 2 bearing an N,N-dimethyl-
amino group on one phenyl ring and either one or preferably 
two ortho-oriented fluoro or chloro groups on the other 
phenyl ring retained the in vitro potencies in a colorectal 
cancer LSI 74T cell proliferation assay. The diarylacetylenes 
2 also possessed the desired property of having minimal 
effects on the cardiac potassium hERG charmel. Molecular 
docking studies suggested that diarylacetylenes and hetero-
cyclic counterparts, like their stilbene counterparts, targeted 
the catalytic subunit (MAT2A) of MAT2. 
We performed additional structure-activity studies with a 
view to obtaining improved potency, solubility and bioavail-
ability relative to the sparingly water-soluble 4-(2,6-difluo-
rophenyl)ethynyl)-N,N-dimethylaniline (2). Initial efforts 
focused on replacing the N,N-dimethylamino group in 2 
with a heterocyclic ring in place of the N,N-dimethylamino 
group as in the heterocyclic-substituted diphenylacetylenes 
4 (FIG. 1), A Sonogashira coupling of 2,6-difluoropheny-
lacetylene (3) with 4-iodophenyl-substituted heterocycles 
Embodiments of the halogenated phenylethynyl-substi-
tuted benzenes and heterocycles of the present disclosure 
include wherein at least two of X1 through X5 are halo 
groups, e.g., wherein at least two ofX1 through X5 are either 50 
(i) a fluoro and chloro, (ii) both fluoro, (iii) both chloro 
groups, and wherein both R1 and R2 are lower alkyl groups, 
e.g., methyl, ethyl, or butyl groups. Preferably X1 and/or X5 
are halo groups, e.g., the phenylethynyl-substituted ben-
zenes and heterocycles have one or two halogen substituents 55 
at ortho-positions relative to the acetylenic linkage, and X2 
through X4 are H or a lower alkyl or alkoxy. In some 
embodiments, the halogenated phenylethynyl-substituted 
benzenes and heterocycles include compounds, or a phar-
maceutically acceptable salt thereof, where Y3 is NR1R2 , 60 
and Y1 , Y2 , Y4 , and Y5 independently represent H, a lower 
alkyl, or NR1R2 . In other embodiments, Y3 is NR1R2 , and 
Y1 , Y2 , Y4 , and Y5 independently represent H or a lower 
alkyl, e.g. Y1 , Y2 , Y4 , and Y5 represent H. In still further 
embodiments, at least one of R1 , or R2 , is a lower alkyl. 65 provided access to the oxopiperidinyl, morpholino, N-meth-
ylpiperazinyl, N-pyrrolyl, and 2,5-dimethyl-N-pyrrolyl ana-
logs 4a-4e (Table 1). The N-pyrrolyl analog 4d showed 
Pharmaceutical compositions of the present disclosure 
include a pharmaceutically acceptable carrier and one or 
US 10,449,186 B2 
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activity in a cell proliferation assay comparable to 4-((2,6-
difluorophenyl)ethynyl)-N,N-dimethylaniline (2) at I µM 
concentration but considerably diminished activity at I 00 
nM. 
Table I below provides inhibition of proliferation (%) of 
colon cancer LSI 74T cells for certain heterocyclic-substi-
tuted phenylethynyl benzenes of the present disclosure at 
various concentrations as represented by compound 4 in 
FIG. 1, e.g. formula (II). Table I also provides such data for 
2,6-difluorophenyl-4 '-(N,N-dimethy !amino )pheny !acety-
lene (2) for comparison. 
TABLE I 
Compound C-4' Substituent 10 µM 1 µM 100 nM 
2a N,N-dimetbylamino 99.5 ± 85.2 ± 
0.1 0.5 
4a 1-piperidinyl-2-one 68.1 ± 6.4 ± 
6.9 11.0 
4b N-morpholino 32.1 ± 13.0 ± 
9.8 2.5 
4c N'-metbyl-N-piperazinyl 99.6 ± 19.9 ± 
0.2 18.2 
4d N-pyrrolyl 96.7 ± 77.5 ± 11.0 ± 
1.9 9.2 18.1 
4e 2,5-dimetbyl-N-pyrrolyl 78.8 ± 20.9 ± 
4.8 10.0 
a data from Sviripa et al., "Halogenated diarylacetylenes repress c-myc expression in cancer 
cells", Bioorg Med Chem Lett 2014, 24:3638-40. 
Because heterocyclic variants in the stilbene series in 
which the N,N-dimethylaniline ring in I (FIG. 1) was 
replaced by either an N,N-dimethylaminopyridine or an 
Heterocycle or 
Compound Ary! ring 
8 
N,N-dimethylaminopyrimidine ring exhibited improved 
solubility and minimal hERG activation, we next focused on 
replacing the N,N-dimethylaniline ring in the diarylacety-
lene series with a heterocyclic ring as in the phenylethynyl-
5 substituted heterocycles represented by compound 5 in FIG. 
1, e.g., formula (III). A Sonogashira coupling of 2,6-difluo-
rophenylacetylene with iodo-substituted heterocycles pro-
vided access to most these analogs (Table 2). In some cases, 
such as the synthesis of 5nn-5oo, it was preferable to couple 
10 2,6-difluorophenylacetylene to l-chloro-4-iodoisoquinoline 
15 
20 
25 
and subsequently to utilize a nucleophilic aromatic substi-
tution reaction to replace the chloro group with a secondary 
amine. Yet another approach involved the coupling of 2,6-
difluorophenylacetylene to l-amino-4-iodoisoquinoline to 
afford 4-(2,6-difluorophenyl)ethynyl)isoquinolin-1-amine 
and the subsequent N,N-dimethylation of the amino group 
using 1,2-bis[(dimethylamino)methylene]hydrazine via an 
intermediate 1,2,4-triazole, but this latter process proceeded 
in a lower overall yield than the yield in the nucleophilic 
aromatic substitution reaction. As summarized in Table 2, 
using these approaches, we synthesized 2,6-difluoropheny-
lethynyl-substituted heterocycles including pyridines 5a-5c, 
pyrazine 5d, indoles 5e-5f, IH-indazoles 5g-5k, IH-pyrrolo 
[2,3-b ]pyridine 51, quinolines 5m-5ff, isoquinolines 5gg-
5oo, 1,6-naphthyridine Sqq, and quinazoline 5rr. 
Table 2 below provides inhibition of cell proliferation (%) 
of colon cancer LSI 74T cells by 2,6-difluorophenylethynyl-
substituted heterocycles represented by compound 5 in FIG. 
1, e.g. formula (III), of the present disclosure at various 
concentrations. 
Positiona 10 µM 1 µM 100 nM 30 nM 
2b N,N-dimetbylaniline C-4 99.5 ± 0.1 85.2 ± 0.5 57 ± 1.2 
5a N,N-dimetbylpyridin- C-6 85.2 ± 3.8 68.9 ± 1.3 15.1 ± 7.4 
3-arnine 
Sb N,N-dimetbylpyridin- C-5 83.6 ± 7.8 77.9 ± 7.0 0 ± 23.7 
2-arnine 
Sc 2-(lH-pyrrol-1- C-5 95.3 ± 0.8 80.5 ± 6.6 0 ± 27.7 
yl )pyridine 
5d N,N-dimetbylpyrazin- C-5 91.6 ± 3.0 22.9 ± 9.8 
2-arnine 
Se lH-indole C-5 91.5 ± 3.5 52.9 ± 5.9 
Sf N-metbylindole C-5 95.2 ± 1.0 77.7 ± 13.6 3.0 ± 5.6 
5g lH-indazole C-4 96.2 ± 2.0 19.8 ± 13.6 
5h lH-indazole C-5 82.9 ± 9.8 17.6 ± 7.9 
5i lH-indazole C-6 97.0 ± 1.1 81.5 ± 2.9 
5j N-metbylindazole C-5 94.6 ± 3.5 58.4 ± 9.6 0 ± 24.5 
5k N-metbylindazole C-6 98.1 ± 0.4 85.9 ± 5.4 0 ± 22.7 
51 1H-pyrrolo[2,3- C-5 77.9 ± 8.9 17.3 ± 12.0 
b]pyridine 
Sm quinoline C-2 93.8 ± 1.7 67.3 ± 13.6 6.1 ± 27.0 
Sn quinoline C-3 90.4 ± 1.0 41.7 ± 6.5 0 ± 5.1 
So quinoline C-4 59.0 ± 7.5 15.4 ± 9.1 
Sp 2-chloroquinoline C-3 85.1 ± 6.2 28.4 ± 10.5 
5q 4-chloroquinoline C-3 80.4 ± 13.7 51.5 ± 20.4 0 ± 26.3 
Sr quinolin-6-arnine C-3 9.2 ± 15.7 
5s 7-fluoroquinoline C-3 95.1 ± 1.6 69.4 ± 4.5 14.8 ± 5.5 
St 8-fluoroquinoline C-3 89.1 ± 8.2 63.6 ± 8.4 8.8 ± 5.1 
Su 7-chloroquinoline C-4 74.3 ± 0.2 36.0 ± 0.4 
5v quinoline C-5 94.7 ± 2.9 43.1 ± 11.2 
5w quinoline C-6 80.1 ± 1.0 11 ± 30.4 
5x quinoline C-7 99.4 ± 0.3 90.7 ± 0.6 2.9 ± 14.0 
Sy quinoline C-8 92.7 ± 2.9 47.6 ± 3.5 
5z 2-chloroquinoline C-6 63.3 ± 2.3 21.2 ± 11.4 
5aa 4-chloroquinoline C-6 89.7 ± 4.3 43.8 ± 10.8 
5bb 4-chloroquinoline C-7 70.8 ± 4.8 23.1 ± 8.3 
5cc quinolin-4-arnine C-6 93.9 ± 0.4 66.2 ± 3.1 0 ± 5.4 
5dd quinolin-4-arnine C-7 97.7 ± 2.2 23.6 ± 2.5 
See N,N-dimetbylquinoline- C-6 38.7 ± 4.3 2.0 ± 11.9 
2-arnine 
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-continued 
Heterocycle or 
Compound Ary! ring Positiona 10 µM 1 µM 100 nM 30 nM 
5ff N,N-dimethylquinoline- C-6 95.5 ± 2.0 81.3 ± 1.4 0 ± 12.9 
4-arnine 
5gg isoquinoline C-1 96.7 ± 0.2 35.4 ± 15.0 
5hh isoquinoline C-4 87.9 ± 1.0 16.5 ± 2.1 
5ii isoquinoline C-5 93.6 ± 0.5 64.2 ± 6.1 
5jj isoquinoline C-6 82.4 ± 10.2 11.6 ± 21.3 
5kk 1-chloroisoquinoline C-4 94.0 ± 0.5 48.1 ± 18.1 0.8 ± 36.1 
511 7-fluoroisoquinoline C-1 96.2 ± 0.1 71.1 ± 3.5 0 ± 5.2 
5mm isoquinolin-1-arnine C-4 93.1 ± 1.6 86.2 ± 1.6 35.5 ± 1.7 
5nn N,N-dimethylisoquinolin- C-4 97.6 ± 1.5 99.5 ± 0.1 81.7 ± 2.1 86.0 ± 2.0 
1-arnine 
Sao N-methylisoquinolin- C-4 98.9 ± 1.0 99.8 ± 0.2 99.5 ± 0.5 94.5 ± 1.5 
1-arnine 
5pp 1-( 4-methylpiperazin- C-4 100 ± oc 23.2 ± 9.4c 
1-yl)isoquinoline 
5qq N,N-dimethyl-1,6- C-8 85.2 ± 1.0 87.9 ± 0.8 59.5 ± 3.5 
naphthyridin-5-amine 
5rr quinazoline C-7 96.3 ± 0.8 33.8 ± 4.8 
aposition of attachment of 2,6-difluorophenylethynyl group; 
bdata from Sviripa et al., "Halogenated diarylacetylenes repress c-myc expression in cancer cells", Bioorg Med Chem Lett 2014, 24: 
3638-40; 
ctested as the hydrochloride salt. 
At 10 µM concentrations, most of the 2,6-difluoropheny-
lethynyl-substituted heterocycles 5 in Table 2 displayed 
potent effects on LSI 74T colon cancer cell proliferation 
assays, and at 1 µM concentrations, several pyridines 5b and 
25 physical propentJes (e.g., water solubility), suggest that 
phenylethynyl-substituted hetrepress colon cancer prolifera-
tion through similar mechanisms. Additional studies of these 
phenylethynyl-substituted heterocycles are the subject of 
Sc, one indole 5f, two lH-indazoles 5i and 5k, two quino-
lines 5x and 5ff, and four isoquinolines 5mm-5oo and Sqq 30 
showed greater than 75% inhibition. Two candidates that 
stood out with respect to potency among the 2,6-difluoro-
phenylethynyl-substituted heterocycles 5 were 4-(2,6-dif-
luorophenyl)ethynyl)-N,N-dimethylisoquinolin-1-amine 
(5nn) and 4-(2,6-difluorophenyl)ethynyl)-N-methylisoqui- 35 
nolin-1-amine ( 500 ). In addition, several of the difluorinated 
phenylethynyl-substituted heterocycles, such as 5pp and 
Sqq, furnished completely water-soluble hydrochloride 
salts. In summary, we identified heterocyclic variants 5 with 
potency and/or water solubility surpassing that of the parent 
compound, 4-((2,6-difluorophenyl)ethynyl)-N,N-dimethyl-
aniline (2). 
40 
45 
Variability in a MAT2A inhibition assay using a molyb-
date colorimetric assay for phosphate made the measure-
ment of cell-cycle inhibition a preferred analytical tool for 
assessing the potency of diarylacetylenes. We tested the 
effect of these heterocyclic-substituted diphenylacetylenes 4 
(Table 1) and fluorinated, phenylethynyl-substituted hetero-
cycles 5 (Table 2) on the proliferation of LSI 74T colon 
cancer cells. As shown in the western blot (FIG. 2A), the so 
most active compounds 2, 5nn and 500 inhibited cyclin Dl 
expression at 300 nM concentrations and, as expected for a 
cell-cycle inhibitor, induced p21 mfl!Cipl at the same time. 
Unlike the diarylacetylene series in which the N-methyl-
anilino and N,N-dimethylanilino analogs of 2 showed com- 55 
parable activity in inhibiting LSI 74T cell proliferation (i.e., 
2, IC50 25.1 nM), the N-methylation pattern in the phenyl-
ethynyl-substituted heterocycles indicated that the N-meth-
ylaminoisoquinoline analog 500 (IC50 4.2 nM) was more 
potent than the N,N-dimethylaminoisoquinoline analog 5nn 60 
(IC50 11.8 nM) (FIG. 2B). In summary, phenylethynyl-
substituted heterocycles 5 inhibited the proliferation of 
LS 17 4 T colon cancer cells by altering the expression of 
c-myc and thereby inducing p21 mfl!Cipl. These results are 
consistent with prior findings using halogenated stilbenes 1 65 
and diarylacetylenes and given the absence of isomerization 
in 5 relative to stilbenes, improved potency, and improved 
on-going investigations. 
We also focused on phenylethynyl-substituted hetero-
cycles represented by compound 7 in FIG. 1, e.g., formula 
(III). A Sonogashira coupling of 4-amino, 4-N-methyl-
amino- or 4-N,N-dimethylaminoacetylene with iodo-substi-
tuted fluorinated heterocycles provided access to these ana-
logs 7 (Table 3). 
TABLE 3 
Com- Heterocyclic 
pound ring Phenyl ring 300 nM 100 nM 30 nM 
7a 2,6-difluoro-4- C6Hs 12.2 ± 24.7 ± 5.3 ± 
pyridine 7.1 3.7 7.9 
7b 2,6-difluoro-4- C6 H4-4-NH2 36.2 ± 30.5 ± 11.4 ± 
pyridine 4.5 2.2 7.8 
7c 2,6-difluoro-4- C6 H4-4-NHCH3 62.6 ± 49.5 ± 20.3 ± 
pyridine 1.3 5.5 5 
7d 2,6-difluoro-4- C6 H4-4-N(CH3h 60.6 ± 20.4 ± 16.7 ± 
pyridine 5.2 0.5 7.7 
At 300 nm concentrations, several of the 2,6-difluoro-4-
pyridylethynyl-substituted benzenes 7 in Table 3 displayed 
potent effects on LSI 74T colon cancer cell proliferation 
assays. Potency in such in vitro tests are not the only 
criterion for advancing compounds forward to clinical stud-
ies, and additional studies, experimental and computational, 
suggested that these compounds 7 possessed minimal tox-
icity and improved ADME parameters. Several of these 
compounds 7 also showed very promising activity using in 
vivo xenograft studies. 
EXAMPLES 
The following examples are intended to illustrate further 
certain, preferred embodiments of the invention and are not 
limiting in nature. Those skilled in the art will recognize, or 
be able to ascertain, using no more than routine experimen-
tation, numerous equivalents to the specific substances and 
procedures described herein. 
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Materials 
Chemicals were purchased from Sigma Aldrich or Fisher 
Scientific or were synthesized according to literature proce-
dures. Solvents were used from commercial vendors without 
further purification unless otherwise noted. Nuclear mag- 5 
netic resonance spectra were determined on a Varian (1 H, 
400 MHz; 13C, 100 Mz) and Bruker (1 H, 700 MHz; 13C, 176 
Mz) instruments. High resolution electrospray ionization 
(ESI) mass spectra were recorded on a LTQ-Orbitrap Velos 
mass spectrometer (Thermo Fisher Scientific, Waltham, 10 
Mass., USA). The FT resolution was set at 100,000 (at 400 
m/z). Samples were introduced through direct infusion using 
a syringe pump with a flow rate of 5 µUmin. MALDI mass 
spectra were obtained on a Bruker Utraflexstreme time-of-
flight mass spectrometer (Billerica, Mass.), using DHB 15 
(2,5-dihydroxybenzoic acid) matrix. Purity of compounds 
was established by combustion analyses by Atlantic Micro-
labs, Inc., Norcross, Ga. Compounds were chromatographed 
on preparative layer Merck silica gel F254 unless otherwise 
indicated. 
General procedure for the Sonogashira coupling of 2,6-
difluorophenylacetylene with aryl iodides or heteroaryl 
iodides. 
20 
To a mixture of 2.1 mmol of an aryl iodide or heteroaryl 
iodide, 3 mmol of diisopropylethylamine, 0.02 mmol of 25 
Pd(PPh3)4 , and 0.02 mmol of Cul in 7 mL of water was 
added 2 mmol of 2,6-difluorophenylacetylene. The mixture 
was stirred for 1-2 hat 75° C. The mixture was cooled, and 
the product was collected by filtration or extraction using 
dichloromethane. The products 4 or 5 were purified by 30 
recrystallization and/or chromatography as noted below. 
1-( 4-( (2,6-Difluorophenyl)ethynyl)phenyl)piperidin-2-
one (4a). Yield 75%; preparative layer chromatography 
using 1:10 methanol-dichloromethane (Rf=0.52); mp 148-
1500 C. NMR (400 MHz, DMSO-d6) Ii 7.58 (d, 1=8.5 Hz, 35 
2H), 7.56-7.47 (m, lH), 7.40 (d, 1=8.5 Hz, 2H), 7.26 (t, 1=8 
Hz, 2H), 3.64 (t, 1=5.6 Hz, 2H), 2.42 (t, lr=6.3 Hz, 2H), 
1.94-1.77 (m, 4H). 13C NMR (101 MHz, DMSO-d6) Ii 
169.01, 162.01 (dd, 1=5.2, 251.5 Hz, 2C), 144.53, 131.78 
(2C), 131.39 (t, 1=10 Hz), 126.19 (2C), 118.35, 111.94 (dd, 40 
1=5.3, 18.2 Hz, 2C), 100.77 (t, 1=19.8 Hz), 98.63 (t, 1=3.1 
Hz), 75.77, 50.29, 32.70, 22.91, 20.79. HRMS (ESI) calcd 
for C19H16F2NO [MH+]: 312.1194. Found: 312.1195. Anal. 
Calcd for C19H15F2NO: C, 73.30; H, 4.86; N, 4.50, Found: 
12 
Hz), 114.49 (2C), 111.8 (dd, 1=5.3, 18.2 Hz, 2C), 109.85, 
101.59 (t, 1=19.9 Hz), 100.22 (t, 1=3 Hz), 74.17, 54.35 (2C), 
46.87 (2C), 45.73. HRMS (ESI) calcd for C19H19F2N2 
[MH+]: 313.1511. Found: 313.1489. Anal. Calcd for 
C19H18F2N2 : C, 73.06; H, 5.81; N, 8.97. Found: C, 72.84; H, 
5.75; N, 8.89. 
1-( 4-( (2,6-Difluorophenyl)ethynyl)phenyl)-1 H-pyrrole 
(4d). Yield 79%; preparative layer chromatography using 
1:5 ethyl acetate-hexane (Rf=0.68); mp 122-124° C. 1H 
NMR (400 MHz, DMSO-d6) ll 7.76-7.61 (m, 4H), 7.60-7.49 
(m, lH), 7.48 (t, 1=2.2 Hz, 2H), 7.32-7.17 (m, 2H), 6.31 (t, 
1=2.2 Hz, 2H). 13C NMR (101 MHz, DMSO-d6) Ii 162.01 
(dd, 1=5, 251.5 Hz, two C), 140.3, 132.98 (2C), 131.36 (t, 
1=10.1 Hz), 119.15 (2C), 118.92 (2C), 117.61, 111.93 (dd, 
1=5.4, 18.3 Hz, 2C), 111.19 (2C), 100.91 (t, 1=19.7 Hz), 
98.45 (t, 1=3 Hz), 76.09. HRMS (ESI) calcd for C18H12F2N 
[MH+]: 280.0932. Found: 280.0924. Anal. Calcd for 
C18HuF2N: C, 77.41; H, 3.97; N, 5.02. Found: C, 77.20; H, 
4.21; N, 4.89. 
1-( 4-( (2,6-Difluorophenyl)ethynyl)phenyl)-2,5-dimethyl-
1 H-pyrrole (4e). Yield 84%; colunm chromatography using 
1:10 ethyl acetate-hexane; mp 124-126° C. 1H NMR (400 
MHz, DMSO-d6) Ii 7.71 (d, 1=8.4 Hz, 2H), 7.62-7.51 (m, 
lH), 7.36 (d, 1=8.5 Hz, 2H), 7.30-7.25 (m, 2H), 5.83 (s, 2H), 
2.00 (s, 6H). 13C NMR (101 MHz, DMSO-d6) ll 162.07 (dd, 
1=5.2, 251.8 Hz, 2C), 139.2, 132.43 (2C), 131.66 (t, 1=10.2 
Hz), 128.49 (2C), 127.55 (2C), 120.42, 111.96 (dd, 1=5.3, 19 
Hz, 2C), 106.48 (2C), 100.69 (t, 1=19.7 Hz), 98.05 (t, 1=3 
Hz), 76.71, 12.86 (2C). HRMS (ESI) calcd for C20H16F2 N 
[MH+]: 308.1245, Found: 308.1229. Anal. Calcd for 
C20H15F2N: C, 78.16; H, 4.92; N, 4.56. Found: C, 77.91; H, 
5.03; N, 4.42. 
6-((2,6-Difluorophenyl)ethynyl)-N,N-dimethylpyridin-3-
amine (5a). Yield 68%; preparative layer chromatography 
using 1:2 ethyl acetate-hexane (Rf=0.53); mp 120-122° C. 
1H NMR (400 MHz, DMSO-d6) Ii 8.13 (d, 1=3 Hz, lH), 
7.55-7.46 (m, lH), 7.44 (d, 1=8.7 Hz, lH), 7.29-7.2 (m, 2H), 
7.06 (dd, 1=3.1, 8.8 Hz, lH), 3 (s, 6H). 13C NMR (101 MHz, 
DMSO-d6) Ii 162.01 (dd, 1=5.3, 251.2 Hz, 2C), 145.52, 
134.97, 130.95 (t, 1=10.1 Hz), 127.79, 127.47, 117.6, 111.96 
(dd, 1=5.3, 18.2 Hz, 2C), 101.11 (t, 1=19.8 Hz), 99.79 (t, 
1=3.1 Hz), 72.88, 39.33 (2C). HRMS (ESI) calcd for 
C15H13F2N2 [MH+]: 259.1041. Found: 259.1023. Anal. 
Calcd for C15H12F2N2 : C, 69.76; H, 4.68; N, 10.85. Found: 
C, 73.04; H, 4.85; N, 4.52. 45 C, 69.61; H, 4.85; N, 10.83. 
4-( 4-( (2,6-Difluoropheny l)ethynyl )pheny l)morpholine 
(4b). Yield 67%; colunm chromatography using 1:5 ethyl 
acetate-hexane and recrystallized from hexane; mp 144-
1450 C. 1H NMR (400 MHz, DMSO-d6) Ii 7.53-7.44 (m, 
lH), 7.42 (d, 1=8.9 Hz, 2H), 7.22 (t, 1=7.9 Hz, 2H), 6.98 (d, 50 
1=8.8 Hz, 2H), 3.73 (t, 1=4.8 Hz, 4H), 3.2 (t, 1=4.9 Hz, 4H). 
13C NMR (101 MHz, DMSO-d6) ll 161.85 (dd, 1=5.3, 250.6 
Hz, 2C), 151.36, 132.57 (2C), 130.51 (t, 1=10.1 Hz), 114.35 
(2C), 111.89 (dd, 1=5.4, 250.6 Hz, 2C), 110.38, 101.55 (t, 
1=19.9 Hz), 100.09 (t, 1=3 Hz), 74.28, 65.91 (2C), 47.21 55 
(2C). HRMS (ESI) calcd for C18H16F2NO [MH+]: 
300.1194. Found: 300.1195. Anal. Calcd for C18H15F2 NO: 
C, 72.23; H, 5.05; N, 4.68. Found: C, 71.98; H, 5.09; N, 
4.72. 
5-((2,6-Difluorophenyl)ethynyl)-N,N-dimethylpyridin-2-
amine (5b). Yield 79%; preparative layer chromatography 
using 1:5 ethyl acetate-hexane (Rf=0.41); mp 110-112° C. 
1H NMR (700 MHz, DMSO-d6) Ii 8.29 (d, 1=2.1 Hz, lH), 
7.64 (dd, 1=2.4, 8.9 Hz, lH), 7.53-7.43 (m, lH), 7.22 (t, 
1=7.9 Hz, 2H), 6.68 (d, 1=8.9 Hz, lH), 3.08 (s, 6H). 13C 
NMR (176 MHz, DMSO-d6) ll 161.74 (dd, 1=5.2, 250.7 Hz, 
2C), 158.12, 150.93, 139.51, 130.56 (t, 1=10.1. Hz), 111.81 
(dd, 1=3.9, 20.2 Hz, 2C), 105.54, 104.57, 101.48 (t, 1=19.8 
Hz), 98.02 (t, 1=3 Hz), 76.11, 37.52 (2C). HRMS (ESI) calcd 
for C15H13F2N2 [MH+]: 259.1041. Found: 259.1023. Anal. 
Calcd for C15H12F2 N2 : C, 69.76; H, 4.68; N, 10.85. Found: 
C, 69.49; H, 4.81; N, 10.76. 
5-((2,6-Difluorophenyl)ethynyl)-2-(lH-pyrrol-1-yl)pyri-
1-( 4-( (2,6-Difluorophenyl)ethynyl)phenyl)-4-methylpip-
erazine (4c). Yield 60%, preparative layer chromatography 
using 1:10 methanol-dichloromethane (Rf=0.43); mp 126-
1280 C. 1H NMR (400 MHz; DMSO-d6) Ii 7.53-7.42 (m, 
lH), 7.39 (d, 1=8.8 Hz, 2H), 7.22 (t, 1=7.9 Hz, 2H), 6.96 (d, 
1=8.9 Hz, 2H), 3.24 (t, 1=4.9 Hz, 4H), 2.43 (t, 1=5.l Hz, 4H), 
2.21 (s, 3H). 13C NMR (101 MHz, DMSO-d6) ll 161.82 (dd, 
1=5.4, 250.6 Hz, 2C), 151.21, 132.56 (2C), 130.43 (t, 1=10.1 
60 dine (5c). Yield 66%, preparative layer chromatography 
using 1:5 ethyl acetate-hexane (Rf=0.47) and recrystalliza-
tion from abs. ethanol; mp 121-123° C. 1H NMR (700 MHz 
DMSO-d6) ll 8.63 (d, 1=2.2 Hz, lH), 8.12 (dd, 1=2.3, 8.6 Hz, 
lH), 7.81 (d, 1=8.6 Hz, lH), 7.73 (t, 1=2.3 Hz, 2H), 
65 7.62-7.51 (m, lH), 7.28 (t, 1=8 Hz, 2H), 6.34 (t, 1=2.3 Hz, 
2H). 13C NMR (176 MHz, DMSO-d6) Ii 162.02 (dd, 1=5, 
252 Hz, 2C), 151.04, 150.19, 141.74, 131.8 (t, 1=10.1 Hz), 
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118.35 (2C), 114.63, 112.07 (m, 4C), 111.27, 100.54 (t, 
1=19.7 Hz), 95.5 (t, 1=2.9 Hz), 78.6. HRMS (ESI) calcd for 
C17H11F2 N2 [MH+]: 280.0885. Found: 280.0886. Anal. 
Calcd for C17H10F2N2 : C, 72.85; H, 3.60; N, 10.00. Found: 
14 
6-((2,6-Difluorophenyl)ethynyl)-lH-indazole (5i). Yield 
87%, colunm chromatography using 1: 1 ethyl acetate-
hexane; mp 192-194° C. 1H NMR (400 MHz, DMSO-d6) Ii 
13.31 (s, lH), 8.15 (s, lH), 7.85 (d, 1=8.3 Hz, lH), 7.77 (s, 
C, 72.74; H, 3.69; N, 9.84. 5 l=l.2 Hz, lH), 7.6-7.48 (m, lH), 7.33-7.21 (m, 3H). 13C 
NMR (101 MHz, DMSO-d6) ll 162.09 (dd, 1=5.2, 251.5 Hz, 
2C), 139.31, 133.87, 131.44 (t, 1=10.2 Hz), 123.20, 123.04, 
121.37, 118.43, 113.63, 111.99 (dd, 1=5.3, 19 Hz, 2C), 
5-( (2, 6-Difluoropheny l)ethyny 1)-N,N -dimethy lpyrazin-2-
amine (5d). Yield 73%, colunm chromatography using 1:10 
ethyl acetate-hexane; mp 137-138° C. 1H NMR (400 MHz, 
DMSO-d6) Ii 8.3 (d, 1=1.4 Hz, lH), 8.19 (d, 1=1.4 Hz, lH), 
7.52 (m, lH), 7.25 (t, 1=8 Hz, 2H), 3.13 (s, 6H). 13C NMR 10 
(101 MHz, DMSO-d6) Ii 161.93 (dd, 1=251.5, 5.2 Hz, 2C), 
152.96, 145.35, 131.25 (t, 1=10.1 Hz), 130.64, 123.25, 
111.93 (dd, 1=5.2, 18.6 Hz, 2C), 100.85 (t, 1=19.8 Hz), 97.31 
(t, 1=3 Hz), 75.74, 37.2 (2C). HRMS (ESI) calcd for 
C14H12F2 N3 [MH+]: 260.0994. Found: 260.0994. Anal. 15 
Calcd for C14H11 F2N3: C, 64.86; H, 4.28; N, 16.21. Found: 
C, 64.63; 4.25; N, 16.39. 
100.94 (t, 1=19.7 Hz), 99.67 (t, 1=3.1 Hz), 75.66. HRMS 
(ESI) calcd for C15H9F2 N2 [MH+]: 255.0728. Found: 
255.0712. Anal. Calcd for C15H8F2 N2 : C, 70.86; H, 3.17; N, 
11.02. Found: C, 70.61; H, 3.06; N, 10.88. 
5-((2,6-difluorophenyl)ethynyl)-1-methyl-1 H-indazole 
(5j). Yield 47%; preparative layer chromatography using 1 :5 
ethyl acetate-hexane (Rf=0.31); mp 107-109° C. 1H NMR 
(700 MHz, DMSO-d6) Ii 8.12 (d, 1=0.9 Hz, lH), 8.06 (s, 
lH), 7.73 (d, 1=8.7 Hz, lH), 7.55 (dd, 1=1.5, 8.7 Hz, lH), 
7 .53-7.48 (m, lH), 7 .25 (t, 1=7 .9 Hz, 2H), 4.08 (s, 3H). 13C 
NMR (176 MHz, DMSO-d6) ll 162.01 (dd, 1=5.2, 251.0 Hz, 
2C), 139.19, 133.06, 130.98 (t, 1=10 Hz), 128.78, 125.17, 
123.39, 113.04, 111.89 (dd, 1=3.8, 20.2 Hz, 2C), 110.54, 
101.2 (t, 1=19.8 Hz), 99.87 (t, 1=3 Hz), 74.38, 35.53. HRMS 
(ESI) calcd for C16H11 F2N2 [MH+]: 269.0885. Found: 
269.0885. Anal. Calcd for C16H10F2N2 : C, 71.64; H, 3.76; 
N, 10.44. Found: C, 71.41; H, 3.75; N, 10.53. 
6-((2,6-Difluorophenyl)ethynyl)-1-methyl- lH-indazole 
(5k). Yield 75%; preparative layer chromatography using 
1:5 ethyl acetate-hexane (Rf=0.35); mp 117-119° C. 1H 
NMR (400 MHz, DMSO-d6) Ii 8.12 (s, lH), 7.99 (s, lH), 
5-((2,6-Difluorophenyl)ethynyl)-lH-indole (Se). Yield 
63%; preparative layer chromatography using 1:5 ethyl 
acetate-hexane (Rf=0.44); mp 131-133° C. 1H NMR (400 20 
MHz, DMSO-d6) ll 11.4 (s, lH), 7.82 (s, lH), 7.52-7.44 (m, 
3H), 7.27 (dd, 1=1.6, 8.5 Hz, lH), 7.23 (t, 1=8 Hz, 2H), 
6.51-6.49 (m, lH). 13C NMR (101 MHz, DMSO-d6) Ii 
161.94 (dd, 1=5.4, 250.5 Hz, 2C), 136.08, 130.44 (t, 1=10.1 
Hz), 127.63, 126.95, 124.24, 124.18, 112.06, 111.81 (dd, 25 
1=5.4, 18.3 Hz, 2C), 111.35, 101.69 (t, 1=19.7 Hz), 101.59, 
101.49 (t, 1=3 Hz), 73.26. HRMS (ESI) calcd for C16H10F 2N 
[MH+]: 254.0776. Found: 254.0760. Anal. Calcd for 
C16H9 F2N: C, 75.88; H, 3.58; N, 5.53. Found: C, 76.07; H, 
3.63; N, 5.41. 30 7.83 (d, 1=8.4 Hz, lH), 7.63-7.47 (m, lH), 7.32-7.2 (m, 3H), 
4.09 (s, 3H). 13C NMR (101 MHz, DMSO-d6) ll 162.09 (dd, 
1=5.2, 251.6 Hz, 2C), 139.09, 132.68, 131.44 (t, 1=10.2 Hz), 
123.56, 123.20, 121.49, 118.42, 113.46, 111.94 (dd, 1=5.2, 
5-((2,6-Difluorophenyl)ethynyl)-1-methyl- lH-indole 
(5f). Yield 76%; colunm chromatography using 1:2 ethyl 
acetate-hexane; trip 100-102° C. 1H NMR (400 MHz, 
DMSO-d6) ll 7.82 (d, l=l.6 Hz, lH) 7.55-7.45 (m, 2H), 7.43 
(d, 1=3 Hz, lH), 7.33 (dd, 1=1.6, 8.5 Hz, lH), 7.24 (t, 1=7.9 35 
Hz, 2H), 6.5 (d, 1=2.6 Hz, lH), 3.82 (s, 3H). 13C NMR (101 
MHz, DMSO-d6) Ii 161.94 (dd, 1=5.4, 250.6 Hz, 2C), 
136.45, 131.28, 130.51 (t, 1=10.1 Hz), 127.96, 124.41, 
124.24, 111.83 (dd, 1=5.3, 19.6 Hz, 2C), 111.45, 110.42, 
101.63 (t, 1=20.0 Hz), 101.28 (t, 1=3 Hz), 100.92, 73.52, 40 
32.63. HRMS (ESI) calcd for C17H12F2N [MH+ ]: 268.0932. 
Found: 268.0917. Anal. Calcd for C17H11 F2 N: C, 76.39; H, 
4.15; N, 5.24. Found: C, 76.17; H, 4.31; N, 5.04. 
4-((2,6-Difluorophenyl)ethynyl)-lH-indazole (5g). Yield 
71 %, colunm chromatography using 1:2 ethyl acetate- 45 
hexane; mp 178-179° C. 1H NMR (400 MHz, DMSO-d6) Ii 
13.45 (s, lH), 8.11 (s, lH), 7.69 (d, 1=7.8 Hz, lH), 7.63-7.52 
(m, lH), 7.47-7.37 (m, 2H), 7.3 (t, 1=8 Hz, 2H). 13C NMR 
(101 MHz, DMSO-d6) Ii 162.05 (dd, 1=5.2, 251.8 Hz, 2C), 
139.64, 132.2, 131.67 (t, 1=10.2 Hz), 126.16, 124.5, 123.35, 50 
112.98, 112.22, 112.05 (dd, 1=5.3, 18.2 Hz, 2C), 100.9 (t, 
1=19.7 Hz), 96.74 (t, 1=3 Hz), 79.12, HRMS (ESI) calcd for 
C15H9 F2N2 [MH+]: 255.0728. Found: 255.0712. Anal. 
Calcd for C15H8 F2N2 : C, 70.86; H, 3.17; N, 11.02. Found: 
18.6 Hz, 2C), 100.88 (t, 1=19.7 Hz), 99.65 (t, 1=3 Hz), 75.81, 
35.58, HRMS (ESI) calcd for C16H11 F2N2 [MH+]: 
269.0885. Found: 269.0886. Anal. Calcd for C16H10F2N2 : 
C, 71.64; H, 3.76; N, 10.44. Found: C, 71.48; H, 3.83; N, 
10.39. 
5-((2,6-Difluorephenyl)ethynyl)-1 H-pyrrolo[2,3-b ]pyri-
dine (51). Yield 45%; column chromatography using 1:2 
ethyl acetate-hexane; mp 192-194° C. 1H NMR (400 MHz, 
DMSO-d6) Ii 11.99 (s, lH), 8.41 (d, 1=2 Hz, lH), 8.22 (d, 
1=2 Hz, lH), 7.59 (t, 1=3 Hz, lH), 7.57-7.47 (m, lH), 7.26 
(t, 1=8 Hz, 2H), 6.52 (dd, 1=1.8, 3.5 Hz, lH). 13C NMR (101 
MHz, DMSO-d6) Ii 161.95 (dd, 1=5.2, 251.2 Hz, 2C), 
147.80, 145.04, 131.21, 131.02 (t, 1=10.3 Hz), 127.83, 
119.20, 111.76 (dd, 1=5, 19 Hz, 2C), 109.53, 101.29 (t, 
1=19.9 Hz), 100.42, 98.22 (t, 1=3 Hz), 75.88. HRMS (ESI) 
calcd for C15H9F2 N2 [MH+]: 255.0728. Found: 255.0710. 
Anal. Calcd for C15H8 F2N2 : C, 70.86; H, 3.17; N, 11.02. 
Found: C, 70.57; H, 3.17; N, 10.88. 
2-((2,6-Difluorophenyl)ethynyl)quinoline (5m). Yield 
83%; colunm chromatography using 1 :5 ethyl acetate-
hexane; mp 127-129° C. 1H NMR (400 MHz, DMSO-d6) Ii 
C, 70.60; H, 3.25; N, 10.92. 
5-((2,6-Difluorophenyl)ethynyl)-lH-indazole (5h). Yield 
25%, preparative layer chromatography using 1 :2 ethyl 
acetate-hexane (Rf=0.63); mp 193-195° C. 1H NMR (700 
MHz, DMSO-d6) ll 13.34 (s, lH), 8.15 (s, lH), 8.08 (s, lH), 
55 8.48 (d, 1=8.5 Hz, lH), 8.09-8.02 (m, 2H), 7.89-7.82 (m, 
lH), 7.76 (d, 1=8.4 Hz, lH), 7.72-7.66 (m, lH), 7.66-7.58 
(m, lH), 7.32 (t, 1=8.1 Hz, 2H). 13C NMR (101 MHz, 
DMSO-d6) Ii 162.44 (dd, 1=5, 252.8 Hz, 2C), 147.66, 
7 .62 ( d, 1=8.6 Hz, lH), 7 .54-7.45 (m, 2H), 7 .25 (t, 1=7 .9 Hz, 60 
2H). 13C NMR (176 MHz, DMSO-d6) Ii 162.01 (dd, 1=5.2, 
251 Hz, 2C), 139.52, 134.15, 130.94 (t, 1=10.1 Hz), 128.85, 
124.98, 122.82, 112.96, 111.88 (dd, 1=3.8, 20.2 Hz, 2C), 
110.94, 101.24 (t, 1=19.8 Hz), 100.03 (t, 1=3 Hz), 74.15. 
HRMS (ESI) calcd for C15H9F2 N2 [MH+]: 255.0728. 65 
Found: 255.0727. Anal. Calcd for C15H8F2 N2 : C, 70.86; H, 
3.17; N, 11.02, Found: C, 70.64; H, 3.22; N, 11.09. 
141.73, 137.07, 132.57 (t, 1=10.2 Hz), 130.62, 128.75, 
128.05, 127.82, 127.15, 124.25, 112.16 (dd, 1=4.6, 19 Hz, 
2C), 99.97 (t, 1=19.7 Hz), 98.51 (t, 1=3 Hz), 75.62. HRMS 
(ESI) calcd for C17H10F2N [MH+]: 266.0776. Found: 
266.0756. Anal. Calcd for C17H9 F2N: C, 76.98; H, 3.42; N, 
5.28. Found: C, 76.73; H, 3.38; N, 5.17. 
3-((2,6-Difluorophenyl)ethynyl)quinoline (5n). Yield 
64%; preparative layer chromatography using 1:10 ethyl 
acetate-hexane (Rf=0.42); mp 115-117° C. 1H NMR (400 
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8.9 Hz, lH), 7.61-7.54 (m, lH), 7.3 (t, 1=8.1 Hz, 2H). 13C 
NMR (101 MHz, DMSO-d6) Ii 163.16 (d, 1=250.1 Hz), 
162.12 (dd, 1=5.1, 252.3 Hz, 2C), 152.29, 147.61 (d, 1=13 
Hz), 139.24 (d, 1=1.3 Hz), 132.07 (t, 1=10.2 Hz), 131.14 (d, 
1=10.3 Hz), 124.09, 118.13 (d, 1=25.5 Hz), 114.95 (d, 1=2.7 
Hz), 112.58 (d, 1=20.6 Hz), 112.10 (dd, 1=5.3, 18.9 Hz, 2C), 
100.4 (t, 1=19.7 Hz), 95.94 (t, 1=2.9 Hz), 78.94. HRMS 
(ESI) calcd for C17H9 F3 N [MH+]: 284.0682. Found: 
284.0661. Anal. Calcd for C17H8 F3N: C, 72.09; H, 2.85; N, 
MHz, DMSO-d6) Ii 9 (d, 1=2.1 Hz, lH), 8.72 (d, 1=2.2 Hz, 
lH), 8.06 (d, 1=8.4 Hz, 2H), 7.85 (t, 1=7.6 Hz, lH), 7.69 (t, 
1=7.6 Hz, lH), 7.64-7.52 (m, lH), 7.30 (t, 1=8.1 Hz, 2H). 
13C NMR (101 MHz, DMSO-d6) Ii 162.12 (dd, 1=5, 252.2 
Hz, 2C), 151.13, 146.64, 139.13, 132.02 (t, 1=10.2 Hz), 5 
131.04, 128.87, 128.29, 127.7, 126.73, 115.41, 112.06 (dd, 
1=5, 18.7 Hz, 2C), 100.46 (t, 1=19.7 Hz), 96.21 (t, 1=3.1 Hz), 
78.9. HRMS (ESI) calcd for C17H10F2 N [MH+]: 266.0776. 
Found: 266.0757. Anal. Calcd for C17H9F2 N; C, 76.98; H, 
3.42; N, 5.28. Found: C, 76.68; H, 3.50; N, 5.11. 10 4.95. Found: C, 71.83; H, 2.94; N, 4.70. 
4-((2,6-Difluorophenyl)ethynyl)quinoline (So). Yield 
68%; colunm chromatography using 1 :5 ethyl acetate-
hexane; mp 101-102° C. 1H NMR (400 MHz, DMSO-d6) Ii 
8.97 (d, 1=4.4 Hz, lH), 8.29 (d, 1=8.1 Hz, lH), 8.12 (d, 1=8.3 
Hz, lH), 7.95-7.84 (m, lH), 7.83-7.75 (m, 2H), 7.70-7.58 15 
(m, lH), 7.34 (t, 1=8.1 Hz, 2H). 13C NMR (101 MHz, 
DMSO-d6) Ii 162.22 (dd, 1=4.9, 252.9 Hz, 2C), 150.26, 
147.50, 132.8 (t, 1=10.2 Hz), 130.44, 129.78, 128.15, 127.1, 
126.35, 124.97, 123.86, 112.21 (dd, 1=5.3, 19 Hz, 2C), 
100.06 (t, 1=19.8 Hz), 94.17 (t, 1=3 Hz), 84.92. HRMS (ESI) 20 
calcd for C17H10F2N [MH+]: 266.0776. Found: 266.0757, 
Anal. Calcd for C17H9 F2 N: C, 76.98; H, 3.42; N, 5.28. 
Found: C, 77.21; H, 3.43; N, 5.24. 
2-Chloro-3-( (2,6-difluorophenyl)ethynyl)quinoline (5p ). 
Yield 53%; colunm chromatography using 1 :5 ethyl acetate- 25 
hexane; mp 137-138° C. 1H NMR (400 MHz, DMSO-d6) Ii 
8.89 (s, lH), 8.1 (d, 1=8.2 Hz, lH), 8 (d, 1=8.5 Hz, lH), 
7.93-7.84 (m, lH), 7.77-7.69 (m, lH), 7.68-7.56 (m, lH), 
7.31 (t, 1=8.1 Hz, 2H). 13C NMR (101 MHz, DMSO-d6) Ii 
162.2 (dd, 1=5, 252.8 Hz, 2C), 148.86, 146.09, 143, 132.47 30 
(t, 1=10.1 Hz), 132.3, 128.28, 128.16, 127.84, 126.14, 
115.72, 112.17 (dd, 1=4.5, 19 Hz, 2C), 100.22 (t, 1=19.7 Hz), 
94.07 (t, 1=2.9 Hz), 82.23. HRMS (ESI) calcd for 
C17H9 ClF2N [MH+]: 300.0386. Found: 300.0368. Anal. 
Calcd for C17H8ClF2 N: C, 68.13; H, 2.69; N, 4.67. Found: 35 
C, 68.16; H, 2.73; N, 4.38. 
4-Chloro-3-((2,6-difluorophenyl)ethynyl)quinoline (5q). 
Yield 40%; recrystallized from methanol; mp 140-142° C. 
1H NMR (400 MHz, DMSO-d6) Ii 9.03 (s, lH), 8.27 (d, 
1=8.4 Hz, lH), 8.14 (d, 1=8.4 Hz, lH), 7.94 (t, 1=7.7 Hz, 40 
lH), 7.84 (t, 1=7.7 Hz, lH), 7.7-7.56 (m, lH), 7.32 (t, 1=8.2 
Hz, 2H). 13C NMR (101 MHz, DMSO-d6) Ii 162.11 (dd, 
1=4.9, 253.1 Hz, 2C), 151.25, 147.27, 143, 132.62 (t, 1=10.2 
Hz), 131.84, 129.65, 129.22, 124.83, 124.17, 115.77, 112.16 
(dd, 1=4.6, 19 Hz, 2C), 100.15 (t, 1=19.7 Hz), 93.43 (t, 1=3 45 
Hz), 84.18. HRMS (ESI) calcd for C17H9ClF2 N [MH+]: 
300.0386. Found: 300.0366. Anal. Calcd for C17H8ClF2 N: 
C, 68.13; H, 2.69; N, 4.67. Found: C, 67.84; H, 2.82; N, 
4.53. 
3-((2,6-Difluorophenyl)ethynyl)-8-fluoroquinoline (5t). 
Yield 79%; recrystallized from methanol; mp 136-137° C. 
1H NMR (400 MHz, DMSO-d6) ll 9.05 (d, 1=2 Hz, lH), 8.8 
(s, lH), 7.97-7.84 (m, lH), 7.75-7.65 (m, 2H), 7.64-7.56 (m, 
lH), 7.31 (t, 1=8.1 Hz, 2H). 13C NMR (101 MHz, DMSO-
d6) Ii 162.15 (dd, 1=5, 252.4 Hz, 2C), 157.08 (d, 1=255.6 
Hz), 151.38 (d, l=l.5 Hz), 139.04 (d, 1=2.9 Hz), 136.37 (d, 
1=12 Hz), 132.25 (t, 1=10.2 Hz), 128.44 (d, 1=2 Hz), 127.91 
(d, 1=8 Hz), 124.26 (d, 1=4.6 Hz), 116.55, 115.22 (d, 1=18.4 
Hz), 112.11 (dd, 1=5, 18.6 Hz, 2C), 100.27 (t, 1=19.7 Hz), 
95.71 (t, 1=3 Hz), 79.59. HRMS (ESI) calcd for C17H9 F3N 
[MH+]: 284.0682. Found: 284.0661. Anal. Calcd for 
C17H8 F3 N: C, 72.09; H, 2.85; N, 4.95. Found; C, 71.79; H, 
2.92; N, 4.95. 
7-Chloro-4-( (2,6-difluorophenyl)ethynyl)quinoline ( Su). 
Yield 80%; colunm chromatography in 1:150 methanol-
dichloromethane; mp 130-132° C., 1H NMR (400 MHz, 
DMSO-d6) ll 8.99 (d, 1=4.4 Hz, lH), 8.25 (d, 1=8.9 Hz, lH), 
8.17 (d, 1=2.1 Hz, lH), 7.83 (dd, 1=2.1, 8.9 Hz, lH), 7.80 (d, 
1=4.5 Hz, lH), 7.7-7.59 (m, lH), 7.34 (t, 1=8.2 Hz, 2H). 13C 
NMR (101 MHz, DMSO-d6) ll 162.24 (dd, 1=4.9, 253.1 Hz, 
2C), 151.62, 147.83, 135.06, 133.04 (t, 1=10.3 Hz), 128.78, 
128.42, 127.32, 127.01, 125.05, 124.22, 112.24 (dd, 1=4.5, 
19 Hz, 2C), 99.89 (t, 1=19.6 Hz), 93.66 (t, 1=3 Hz), 85.43. 
HRMS (ESI) calcd for C17H9ClF2N [MH+]: 300.0386. 
Found: 300.0366. Anal. Calcd for C17H8ClF2 N: C, 68.13; H, 
2.69; N, 4.67. Found: C, 67.96; H, 2.68; N, 4.68. 
5-((2,6-Difluorophenyl)ethynyl)quinoline (5v). Yield 
68%; preparative layer chromatography using 1:10 ethyl 
acetate-hexane (Rf=0.45); mp 98-100° C. 1H NMR (400 
MHz, DMSO-d6) Ii 9.04-9 (m, lH), 8.64 (d, 1=8.2 Hz, lH), 
8.15 (dd, 1=2.5, 8.5 Hz, lH), 7.94 (dd, 1=2.8, 7.2 Hz, lH), 
7.9-7.78 (m, lH), 7.78-7.69 (m, lH), 7.66-7.52 (m, lH), 
7.40-7.23 (m, 2H). 13C NMR (101 MHz, DMSO-d6) Ii 
162.06 (dd, 1=5.1, 251.9 Hz, 2C), 151.47, 147.34, 133.17, 
131.9 (t, 1=10.2 Hz), 131.13, 131.06, 129.35, 127.62, 
122.86, 119.2, 112.06 (dd, 1=5.3, 18.3 Hz, 2C), 100.56 (t), 
95.63 (t, 1=3.1 Hz), 81.48. HRMS (ESI) calcd for 
C17H10F2N [MH+]: 266.0776. Found: 266.0758. Anal. 
3-((2,6-Ditfluorophenyl)ethynyl)quinolin-6-amine (5r). 
Yield 67%; colunm chromatography using 2: 1 ethyl acetate-
hexane; mp 184-185° C. 1H NMR (400 MHz, DMSO-d6) Ii 
8.54 (d, 1=2.1 Hz, lH), 8.26 (d, 1=2.1 Hz, lH), 7.73 (d, 1=9 
Hz, lH), 7.63-7.51 (m, lH), 7.29 (t, 1=8 Hz, 2H), 7.22 (dd, 
1=2.4, 9 Hz, lH), 6.83 (d, 1=2.5 Hz, lH), 5.82 (s, 2H). 13C 
NMR (101 MHz, DMSO-d6) ll 162.10 (dd, 1=5.1, 251.9 Hz, 
2C), 148.05, 145.57, 140.98, 135.88, 131.76 (t, 1=10.2 Hz), 
129.62, 128.76, 123, 115.13, 112.07 (dd, 1=5, 18.7 Hz, 2C), 
104.41, 100.8 (t, 1=19.7 Hz), 97.1 (t, 1=3.1 Hz), 78.02. 
HRMS (ESI) calcd for C17HuF2N2 [MH+]: 281.0885. 
Found: 281.0864.Anal. CalcdforC17H10F2N2 : C, 72.85; H, 
3.60; N, 10.00. Found: C, 72.57; H, 3.64; N, 9.84. 
50 Calcd for C17H9 F2N: C, 76.98; H, 3.42; N, 5.28. Found: C, 
76.80; H, 3.47; N, 5.15. 
6-((2,6-Difluorophenyl)ethynyl)quinoline (5w). Yield 
80%; colunm chromatography using 1 :2 ethyl acetate-
hexane; mp 91-93° C. 1H NMR (400 MHz, DMSO-d6) Ii 
3-((2,6-Difluorophenyl)ethynyl)-7-fluoroquinoline (5s ). 
Yield 87%; colunm chromatography using 1 :5 ethyl acetate-
hexane; mp 142-143° C. 1H NMR (400 MHz, DMSO-d6) Ii 
9.03 (d, 1=2 Hz, lH), 8.77 (d, 1=2.1 Hz, lH), 8.17 (dd, 1=6.3, 
9.1 Hz, lH), 7.83 (dd, 1=2.5, 10.3 Hz, lH), 7.66 (td, 1=2.6, 
55 8.96 (dd, 1=1.8, 4.2 Hz, lH), 8.44 (d, 1=8.1 Hz, lH), 8.33 (d, 
l=l.9 Hz, lH), 8.07 (d, 1=8.7 Hz, lH), 7.86 (dd, l=l.9, 8.7 
Hz, lH), 7.61 (dd, 1=4.2, 8.3 Hz, lH), 7.59-7.52 (m, lH), 
7.29 (t, 1=8.1 Hz, 2H). 13C NMR (101 MHz, DMSO-d6) Ii 
162.12 (dd, 1=5.1, 251.9 Hz, 2C), 151.86, 147.35, 136.13, 
60 132.05, 131.74 (t, 1=10.2 Hz), 131.38, 129.7, 127.75, 
122.44, 119.23, 112.01 (dd, 1=4.9, 18.7 Hz, 2C), 100.67 (t, 
1=19.7 Hz), 98.47 (t, 1=3 Hz), 76.91. HRMS (ESI) calcd for 
C17H10F2N [MH+]: 266.0776. Found: 266.0758. Anal. 
Calcd for C17H9 F2N: C, 76.98; H, 3.42; N, 5.28. Found: C, 
65 76.97; H, 3.33; N, 5.29. 
7-((2,6-Difluorophenyl)ethynyl)quinoline (5x). Yield 
74%; preparative layer chromatography using 1:10 ethyl 
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acetate-hexane (Rf=0.49); mp 123-125° C. 1H NMR (400 
MHz, DMSO-d6 ) Ii 8.98 (dd, 1=1.7, 4.2 Hz, lH), 8.43 (d, 
1=8.2 Hz, lH), 8.21 (d, l=l.l Hz, lH), 8.07 (d, 1=8.4 Hz, 
lH), 7.73 (dd, 1=1.6, 8.4 Hz, lH), 7.66-7.5 (m, 2H), 7.29 (t, 
1=8.1 Hz, 2H). 13C NMR (101 MHz, DMSO-d9 ) Ii 162.13 5 
(dd, 1=5, 252 Hz, 2C), 151.81, 147.12, 136.01, 132.15, 
131.86 (t, 1=10.2 Hz), 129.08, 128.46, 128.24, 122.56, 
122.21, 112.7-111.37 (dd, 1=5, 18.6 Hz, 2C), 100.62 (t, 
1=19.8 Hz), 98.35 (t, 1=3.1 Hz), 77.65. HRMS (ESI) calcd 
for C17H10F2 N [MH+]: 266.0776. Found: 266.0757. Anal. 
10 
Calcd for C17H9 F2N: C, 76.98; H, 3.42; N, 5.28. Found: C, 
77.15;H,328;N, 531. 
8-((2,6-Difluorophenyl)ethynyl)quinoline (5y). Yield 
62%; colunm chromatography using 1 :5 ethyl acetate-
15 
hexane; mp 108-110° C. 1H NMR (400 MHz, DMSO-d6 ) Ii 
9.04 (dd, 1=1.8, 4.2 Hz, lH), 8.47 (dd, 1=1.8, 8.3 Hz, lH), 
8.11 (d, 1=8.2 Hz, lH), 8.08 (dd, 1=1.4, 7.2 Hz, lH), 
7.7-7.62 (m, 2H), 7.6-7.5 (m, lH), 7.28 (t, 1=8 Hz, 2H). 13C 
NMR (101 MHz, DMSO-d6) ll 162.07 (dd, 1=5.2, 251.6 Hz, 20 
2C), 151.47, 147.17, 136.71, 134.39, 131.37 (t, 1=10.2 Hz), 
130, 128.02, 126.3, 122.36, 121.25, 111.94 (dd, 1=5.3, 19 
Hz, 2C), 101.33 (t, 1=19.6 Hz), 97.3 (t, 1=3 Hz), 80.76. 
HRMS (ESI) calcd for C17H10F2N [MH+]: 266.0776. 
Found: 266.0757. Anal. Calcd for C17H9F2 N: C, 76.98; H, 25 
3.42; N, 5.28. Found: C, 76.68; H, 3.30; N, 5.29. 
2-Chloro-6-((2,6-difluorophenyl)ethynyl)quinoline (5z). 
Yield 67%; colunm chromatography using 1 :5 ethyl acetate-
hexane; mp 137-138° C. 1H NMR (400 MHz, DMSO-d6 ) Ii 
8.51 (d, 1=8.7 Hz, lH), 8.39 (s, lH), 8 (d, 1=8.7 Hz, lH), 30 
7.92 (dd, 1=8.7, 1.6 Hz, lH), 7.69 (d, 1=8.6 Hz, lH), 
7.63-7.53 (m, lH), 7.29 (t, 1=8.1 Hz, 2H). 13C NMR (100 
MHz, DMSO-d6 ) ll 162.14 (dd, 1=252, 5.1 Hz, 2C), 151.17, 
146.89, 140.01, 132.81, 131.97, 131.93 (t, 1=10.2 Hz), 
128.64, 126.69, 123.53, 119.89, 112.06, (dd, 1=5.3, 19 Hz, 35 
2C), 100.54 (t, 1=19.8 Hz), 98.05 (t, 1=3 Hz). 77.38. HRMS 
(ESI) calcd for C17H9 ClF2 N [MH+]: 300.0386. Found: 
300.0366. Anal. Calcd for C17H8ClF2N: C, 68.13; H, 2.69; 
N, 4.67. Found: C, 67.93; H, 2.70; N, 4.49. 
4-Chloro-6-( (2,6-difluorophenyl)ethynyl)quinoline (Saa). 40 
Yield 64%; preparative layer chromatography using 1:5 
ethyl acetate-hexane (Rf=0.33) and recrystallization from 
hexane; mp 120-122° C. 1H NMR (700 MHz, DMSO-d6 ) Ii 
8.89 (d, 1=4.7 Hz, lH), 8.33 (d, 1=1.8 Hz, lH), 8.14 (d, 1=8.6 
Hz, lH), 7.96 (dd, 1=1.8, 8.6 Hz, lH), 7.84 (d, 1=4.7 Hz, 45 
lH), 7.67-7.5 (m, lH), 7.29 (t, 1=8 Hz, 2H), 13C NMR, (176 
MHz, DMSO-d6) Ii 162.14 (dd, 1=4.9, 252.3 Hz, 2C), 
151.75, 148.13, 140.97, 132.55, 132 (t, 1=10.1 Hz), 130.46, 
127.06, 125.49, 122.61, 120.88, 112.00 (dd, 1=3.8, 20.1 Hz, 
2C), 100.41 (t, 1=19.7 Hz), 97.85 (t, 1=3 Hz), 77.94. HRMS 50 
(ESI) calcd for C17H9 ClF2 N [MH+]: 300.0386, Found: 
300.0389. Anal. Calcd for C17H8ClF2N: C, 68.13; H, 2.69; 
N, 4.67, Found: C, 67.85; H, 2.79; N, 4.53. 
4-Chloro-7-((2,6-difluorophenyl)ethynyl)quinoline (5bb ). 
Yield 63%; colunm chromatography using 1 :5 ethyl acetate- 55 
hexane and recrystallized from acetonitrile; mp 148-150° C. 
1H NMR (400 MHz, DMSO-d6 ) Ii 8.92 (d, 1=4.7 Hz, lH), 
8.28 (d, 1=1.7 Hz, lH), 8.25 (d, 1=8.7 Hz lH), 7.88 (dd, 
l=l.7, 8.6 Hz, lH), 7.84 (d, 1=4.7 Hz, lH), 7.64-7.52 (m, 
lH), 7.30 (t, 1=8.1 Hz, 2H). 13C NMR (101 MHz, DMSO- 60 
d6) ll 162.16 (dd, 1=5, 252.3 Hz, 2C), 151.83, 148.07, 141.2, 
132.55, 132.16 (t, 1=10.1 Hz), 130.06, 125.83, 124.76, 
123.5, 122.66, 112.08 (dd, 1=5.3, 19 Hz, 2C), 100.4 (t, 
1=19.7 Hz), 97.62 (t, 1=3 Hz), 78.63. HRMS (ESI) calcd for 
C17H9 ClF2N [MH+]: 300.0386. Found: 300.0365. Anal. 65 
Calcd for C17H8ClF2 N: C, 68.13; H, 2.69; N, 4.67. Found: 
C, 68.41; H, 2.97; N, 4.42. 
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6-((2,6-Difluorophenyl)ethynyl)quinolin-4-amine (5cc ). 
Yield 93%; colunm chromatography using 1:10 methanol-
dichloromethane; mp 220-222° C. 1H NMR (700 MHz, 
DMSO-d6 ) ll 8.54 (s, lH), 8.35 (br s, lH), 7.79 (d, 1=8.6 Hz, 
lH), 7.73 (dd, 1=1.7, 8.6 Hz, lH), 7.61-7.51 (m, lH), 7.29 
(t, 1=8 Hz, 2H), 7.27 (s, 2H), 6.62 (d, 1=5.3 Hz, lH). 13C 
NMR (176 MHz, DMSO-d6 ) ll 162.07 (dd, 1=5, 251.6 Hz, 
2C), 152.28, 150.46, 147.61, 131.44, 131.41 (t, 1=10.1 Hz), 
128.67, 126.82, 118.06, 116.27, 111.98 (dd, 1=5, 18.6 Hz, 
2C), 103.1, 100.91 (t, 1=19.8 Hz), 99.23 (t, 1=3 Hz), 76.01. 
HRMS (ESI) calcd for C17HuF2N2 [MH+]: 281.0885. 
Found: 281.0887. Anal. Calcd for C17H10F2N2 : C, 72.85; H, 
3.60; N, 10.00. Found: C, 72.84; H, 3.52; N, 10.06. 
7-((2,6-Difluorophenyl)ethynyl)quinolin-4-amine (5dd). 
Yield 61 %; colunm chromatography using ethyl acetate; mp 
219-221 ° C. 1H NMR (700 MHz, DMSO-d6) Ii 8.37 (br s, 
lH), 8.23 (d, 1=8.6 Hz, lH), 7.94 (s, lH), 7.6-7.54 (m, lH), 
7.51 (dd, 1=1.5, 8.6 Hz, lH), 7.29 (t, 1=8 Hz, 2H), 6.93 (s, 
2H), 6.6 (d, 1=5.1 Hz, lH). 13C NMR (176 MHz, DMSO-d6 ) 
Ii 162.1 (dd, 1=5.0, 251.8 Hz, 2C), 151.45, 151.4, 148.33, 
132.32, 131.63 (t, 1=10.1 Hz), 125.22, 123.49, 121.57, 
118.88, 111.98 (dd, 1=3.7, 20.3 Hz, 2C), 103.21, 100.78 (t, 
1=19.7 Hz), 98.75 (t, 1=2.9 Hz), 76.85, HRMS (ESI) calcd 
for C17HuF2N2 [MH+]: 281.0885. Found: 281.0885. Anal. 
Calcd for C17H10F2 N2 : C, 72.85; H, 3.60; N, 10.00. Found: 
C, 72.57; H, 3.73; N, 9.96. 
General Procedure for the synthesis of N,N-dimethyl-
amino-substituted quinolines by nucleophilic aromatic sub-
stitution. 
A mixture of 130 mg (0.43 mmol) of an appropriate 
chloro-substituted quinoline and 2.2 mL (4.3 mmol, 10 eq) 
of2M methylamine or dirnethylamine in THF was stirred at 
130° C. for 2-3 h in a pressure tube. The mixture was poured 
into water, extracted with dichloromethane, dried over anhy-
drous magnesium sulfate, concentrated and purified by 
chromatography as noted for individual compounds. 
6-((2,6-Difluorophenyl)ethynyl)-N,N-dimethylquinolin-
2-amine (See). Yield 67%; preparative layer chromatogra-
phy using 1:5 ethyl acetate-hexane (Rf=0.53) and recrystal-
lization from abs. ethanol; mp 142-144° C. 1H NMR (700 
MHz, DMSO-d6 ) Ii 8.05 (d, 1=9.1 Hz, lH), 7.98 (d, l=l.9 
Hz, lH), 7.6 (dd, 1=2.0, 8.6 Hz, lH), 7.54 (d, 1=8.6 Hz, lH), 
7.53-7.48 (m, lH) 7.29-7.23 (m, 2H), 7.14 (d, 1=9.2 Hz, lH), 
3.19 (s, 6H). 13C NMR (176 MHz, DMSO-d6 ) ll 161.97 (dd, 
1=5.2, 251.1 Hz, 2C), 157.82, 147.85, 136.93, 131.54, 
131.42, 130.93 (t, 1=10 Hz), 126.25, 121.85, 113.31, 111.88 
(dd, 1=3.9, 20.2 Hz, 2C), 110.48, 101.25 (t, 1=19.8 Hz), 
99.78 (t, 1=2.9 Hz), 75.07, 37.61 (2C). HRMS (ESI) calcd 
for C19H15F2 N2 [MH+]: 309.1198. Found: 309.1198, Anal. 
Calcd for C19H14F2N2 : C, 74.01; H, 4.58; N, 9.09. Found: 
C, 74.04; H, 4.59; N, 9.09. 
6-((2,6-Difluorophenyl)ethynyl)-N,N-dimethylquinolin-
4-amine (5fl). Yield 64%; preparative layer chromatography 
using 1:1 ethyl acetate-hexane (Rf=0.41); mp 118-120° C. 
1H NMR (700 MHz, DMSO-d6) Ii 8.62 (d, 1=5.2 Hz, lH), 
8.22 (d, l=l.9 Hz, lH), 7.94 (d, 1=8.6 Hz, lH), 7.76 (dd, 
l=l.9, 8.6 Hz, lH), 7.55 (m, lH), 7.27 (t, 1=8 Hz, 2H), 6.91 
(d, 1=5.2 Hz, lH), 3.02 (s, 6H). 13C NMR (176 MHz, 
DMSO-d6 ) Ii 162.08 (dd, 1=5.1, 251.7 Hz, 2C), 156.56, 
151.52, 149.18, 131.51 (t, 1=10.1 Hz), 130.73, 130.23, 
128.42, 121.95, 117.04, 111.95 (dd, 1=3.8, 20.2 Hz, 2C), 
108.06, 100.84 (t, 1=19.7 Hz), 99.05 (t, 1=3 Hz), 76.28, 
43.54 (2C). HRMS (ESI) calcd for C19H15F2 N2 [MH+]: 
309.1198. Found: 309.1201. Anal. Calcd for C19H14F2 N2 : 
C, 74.01; H, 4.58; N, 9.09. Found: C, 73.75; H, 4.66; N, 
9.11. 
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1-((2,6-Difluorophenyl)ethynyl)isoquinoline (5gg). Yield 
72%; column chromatography using 1 :5 ethyl acetate-
hexane; mp 120-122° C. 1H NMR (400 MHz, DMSO-d6) Ii 
8.6 (d, 1=5.6 Hz, lH), 8.45-8.37 (m, lH), 8.13-8.05 (m, lH), 
7.97 (d, 1=5.6 Hz, lH), 7.92-7.81 (m, 2H), 7.74-7.57 (m, 5 
lH), 7.35 (t, 1=8.1 Hz, 2H). 13C NMR (101 MHz, DMSO-
d6) Ii 162.44 (dd, 1=5, 252.7 Hz, 2C), 143.08, 142.14, 
135.38, 132.71 (t, 1=10.2 Hz), 131.22, 129.13, 128.6, 
127.47, 125.45, 121.74, 112.21 (dd, 1=5.4, 18.3 Hz, 2C), 
100.04 (t, 1=19.7 Hz), 96.00 (t, 1=3.1 Hz), 80. HRMS (ESI) 10 
calcd for C17H10F2N [MH+]: 266.0776. Found: 266.0758. 
Anal. Calcd for C17H9 F2 N: C, 76.98; H, 3.42; N, 5.28. 
Found: C, 76.92; H, 3.50; N, 5.20. 
4-((2,6-Difluorophenyl)ethynyl)isoquinoline (Shh). Yield 
73%; column chromatography using 1 :5 ethyl acetate- 15 
hexane; mp 102-104° C. 1H NMR (400 MHz, DMSO-d6) Ii 
9.41 (s, lH), 8.79 (s, lH), 8.25 (t, 1=9.l Hz, 2H), 7.99 (t, 
1=7.6 Hz, lH), 7.82 (t, 1=7.6 Hz, lH), 7.68-7.53 (m, lH), 
7.32 (t, 1=8.1 Hz, 2H). 13C NMR (101 MHz, DMSO-d6) Ii 
162.04 (dd, 1=5, 252.1 Hz, 2C), 153.34, 146.2, 134.33, 20 
132.32, 132.06 (t, 1=10.2 Hz), 128.63, 128.57, 127.34, 
123.75, 113.84, 112.09 (dd, 1=4.9, 18.6 Hz, 2C), 100.58 (t, 
1=19.6 Hz), 94.01 (t, 1=3 Hz), 83.24. HRMS (ESI) calcd for 
C17H10F2N [MH+]: 266.0776. Found: 266.0758. Anal. 
Calcd for C17H9 F2N: C, 76.98; H, 3.42; N, 5.28. Found: C, 25 
76.68; H, 3.49; N, 5.10. 
5-((2,6-Difluorophenyl)ethynyl)isoquinoline (5ii), Yield 
85%; column chromatography using 1: 1 ethyl acetate-
hexane; mp 115-117° C. 1H NMR (400 MHz, DMSO-d6) Ii 
9.44 (s, lH), 8.7 (d, 1=5.8 Hz, lH), 8.27 (d, 1=8.3 Hz, lH), 30 
8.11 (dd, 1=1.1, 7.2 Hz, lH), 8.08 (d, 1=5.9 Hz, 1.11), 
7.81-7.72 (m, lH), 7.66-7.55 (m, lH), 7.33 (t, 1=8.1 Hz, 
2H). 13C NMR (101 MHz, DMSO-d6) Ii 162.06 (dd, 1=5.1, 
252 Hz, 2C), 153.14, 144.54, 134.88, 134.71, 131.97 (t, 
1=10.1 Hz), 129.62, 127.91, 127.36, 117.86, 117.53, 112.1 35 
(dd, 1=5.3, 19 Hz, 2C), 100.63 (t, 1=19.6 Hz), 95.41 (t, 1=3 
Hz), 81.86. HRMS (ESI) calcd for C17H10F2N [MH+]: 
266.0776. Found: 266.0756. Anal. Calcd for C17H9 F2N: C, 
76.98; H, 3.42; N, 5.28. Found: C, 76.75; H, 3.47; N, 5.23. 
6-((2,6-difluorophenyl)ethynyl)isoquinoline (5jj). Yield 40 
75%, column chromatographing using 1: 1 ethyl acetate-
hexane; mp 97-99° C. 1H NMR (400 MHz, DMSO-d6) Ii 
9.38 (s, lH), 8.58 (d, 1=6.1 Hz, lH), 8.3 (s, lH), 8.2 (d, 1=8.5 
Hz, lH), 7.9 (d, 1=5.7 Hz, lH), 7.79 (dd, 1=1.6, 8.5 Hz, lH), 
7.68-7.5 (m, lH), 7.3 (t, 1=8.1 Hz, 2H). 13C NMR (101 45 
MHz, DMSO-d6) ll 162.18 (dd, 1=5, 252.1 Hz, 2C), 152.35, 
143.91, 134.84, 132.1 (t, 1=10.2 Hz), 130.25, 129.29, 
128.44, 123.12, 120.19, 112.11 (dd, 1=5.0, 19 Hz, 2C), 
100.37 (t, 1=19.7 Hz), 98.29 (t, 1=3.2 Hz), 78.06. HRMS 
(ESI) calcd for C17H10F2N [MH+]: 266.0776. Found: 50 
266.0757. Anal. Calcd for C17H9 F2N: C, 76.98; H, 3.42; N, 
5.28. Found: C, 77.16; H, 3.39; N, 5.21. 
l -Chloro-4-( (2,6-difluorophenyl )ethyny l)isoquinoline 
(5kk). Yield 48%; preparative layer chromatography using 
1 :5 ethyl acetate-hexane (Rf=0.62) and recrystallization 55 
from abs. ethanol; mp 145-146° C. 1H NMR (700 MHz, 
DMSO-d6) Ii 8.63 (s, lH), 8.39 (d, 1=8.2 Hz, lH), 8.3 (d, 
1=8.3 Hz, lH), 8.1 (ddd, 1=1.2, 6.9, 8.2 Hz, lH), 7.95 (ddd, 
l=l.l, 6.9, 8.3 Hz, lH), 7.66-7.58 (m, lH), 7.33 (t, 1=8.1 Hz, 
2H). 13C NMR (176 MHz, DMSO-d6) Ii 162.06 (dd, 1=4.9, 60 
252.5 Hz, 2C), 151.11, 144.73, 136.29, 133.31, 132.36 (t, 
1=10.1 Hz), 130.35, 126.5, 125.37, 124.82, 114.66, 112.13 
(dd, 1=3.7, 20.1 Hz, 2C). 100.31 (t, 1=19.7 Hz), 93 (t, 1=3.0 
Hz), 84.26. HRMS (ESI) calcd for C17H9ClF2 N [MH+]: 
300.0386. Found: 300.0388. Anal. Calcd for C17H8ClF2 N: 65 
C, 68.13; H, 2.69; N, 4.67. Found: C. 68.06; H, 2.78; N, 
4.61. 
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1-((2,6-Difluorophenyl)ethynyl)-7-fluoroisoquinoline 
(511). Yield 56%; column chromatography using 1 :200 
methanol-dichloromethane; mp 177-178° C. 1 H NMR ( 400 
MHz, DMSO-d6) Ii 8.61 (d, 1=5.5 Hz, lH), 8.23 (dd, 1=5.5, 
9.1 Hz, lH), 8.07-7.96 (m, 2H), 7.83 (td, 1=2.6, 8.9 Hz, lH), 
7.71-7.57 (m, lH), 7.35 (t, 1=8.2 Hz, 2H). 13C NMR (101 
MHz, DMSO-d6) ll 162.43 (dd, 1=5, 252.8 Hz, 2C), 161.17 
(d, 1=249.3 Hz), 142.77 (d, 1=2.4 Hz), 141.58 (d, 1=6 Hz), 
132.93, 132.79 (d, 1=8.6 Hz), 131.15 (d, 1=8.9 Hz), 129.49 
(d, 1=8.8 Hz), 121.79 (d, 1=25.6 Hz), 121.56 (d, l=l.6 Hz), 
112.23 (dd, 1=5, 18.7 Hz, 2C), 108.72 (d, 1=22.2 Hz), 99.91 
(t, 1=19.7 Hz), 95.49 (t, 1=2.7 Hz), 80.54. HRMS (ESI) calcd 
for C17H9 F3N [MH+]: 284.0682. Found: 284.0662. Anal. 
Calcd for C17H8 F3N: C, 72.09; H, 2.85; N, 4.95. Found: C, 
71.98; H, 2.69; N, 4.91. 
4-((2,6-Difluorophenyl)ethynyl)isoquinolin-1-amine 
(5mm). Yield 71%; column chromatography using 1:10 
methanol-dichloromethane and recrystallization from 
methanol; mp 200-201 ° C. 1 H NMR ( 400 MHz, DMSO-d6) 
Ii 8.31 (d, 1=8.3 Hz, lH), 8.17 (s, lH), 8.04 (d, 1=8.2 Hz, 
lH), 7.82 (t, 1=7.6 Hz, lH), 7.59 (t, 1=7.6 Hz, lH), 7.55-7.43 
(m, 3H), 7.26 (t, 1=7.9 Hz, 2H). 13C NMR (101 MHz, 
DMSO-d6) Ii 162.04 (dd, 1=5.4, 250.5 Hz, 2C), 158.49, 
147.85, 136.25, 131.71, 130.77 (t, 1=10 Hz), 126.86, 125, 
124.33, 116.64, 111.85 (dd, 1=5.4, 18.3 Hz, 2C), 102.27, 
102.23 (t, 1=19.9 Hz), 97.26 (t, 1=2.9 Hz), 80.27. HRMS 
(ESI) calcd for C17HuF2N2 [MH+]: 281.0885. Found: 
281.0866. Anal. Calcd for C17H10F2N2 : C, 72.85; H, 3.60; 
N, 10.00. Found: C, 73.13; H, 3.69; N, 9.93. 
4-( (2, 6-difluoropheny l)ethynyl )-N,N-dimethy lisoquino-
lin-1-amine (5nn). Yield 75%; preparative layer chromatog-
raphy using 1:5 ethyl acetate-hexane (Rf=0.47); mp 122-
1240 C. 1H NMR (700 MHz, DMSO-d6) Ii 8.31 (s, lH), 
8.23-8.16 (m, lH), 8.13 (dd, 1=1.2, 8.3 Hz, lH), 7.84 (ddd, 
l=l.2, 6.9, 8.2 Hz, lH), 7.62 (ddd, 1=1.3, 6.8, 8.3 Hz, lH), 
7.56-7.48 (m, lH), 7.28 (t, 1=7.9 Hz, 2H), 3.19 (s, 6H). 13C 
NMR (176 MHz, DMSO-d6) ll 161.72 (dd, 1=5.3, 250.9 Hz, 
2C), 160.63, 145.03, 137.01, 130.96, 130.82 (t, 1=10.1 Hz), 
126.80, 126.2, 124.21, 118.3, 111.91 (dd, 1=3.8, 20.1 Hz, 
2C), 105.07, 101.45 (t, 1=19.8 Hz), 95.96 (t, 1=2.9 Hz), 
81.00, 42.45 (2C). HRMS (ESI) calcd for C19H15F2N2 
[MH+]: 309.1198. Found: 309.1200. Anal. Calcd for 
C19H14F2N2 : C, 74.01; H, 4.58; N, 9.09. Found: C, 73.75; H, 
4.60; N, 9.00. 
4-((2,6-Difluorophenyl)ethynyl)-N-methylisoquinolin-1-
amine (5oo ). Yield 60%, Rf=0.48 (1 :2 ethyl acetate-hexane), 
mp 118-120° C. 1H NMR (400 MHz, DMSO-d6) Ii 8.28 (d, 
1=8.6 Hz, lH), 8.25 (s, lH), 8.08 (t, 1=4.5 Hz, lH), 8.05 (d, 
1=9.l Hz, lH), 7.81 (t, 1=7.5 Hz, lH), 7.61 (t, 1=7.5 Hz, lH), 
7.55-7.44 (m, lH), 7.26 (t, 1=7.9 Hz, 2H), 3.03 (d, 1=4.5 Hz, 
3H). 13C NMR (101 MHz, DMSO-d6) ll 161.61 (dd, 1=5.4, 
250.4 Hz, 2C), 156.29, 147.12, 135.26, 130.99, 130.33 (t, 
1=10.1 Hz), 126.6, 124.05, 123.44, 117.01, 112.01 (dd, 
1=3.8, 20.1 Hz, 2C), 101.78 (t, 1=19.9 Hz), 101.45, 96.88 (t, 
1=2.9 Hz), 79.90, 28.29. HRMS (ESI) calcd for C13H13F2 N2 
[MH+]: 295.1041. Found: 295.1035. Anal. Calcd for 
C18H12F2H2 : C, 73.46; H, 4.11; N, 9.52. Found: C, 73.49; H, 
4.23, N, 9.61. 
4-((2,6-Difluorophenyl)ethynyl)-1-( 4-methylpiperazin-1-
yl)isoquinoline (5pp). Yield 79%, Rf=0.42 (1:10 methanol-
dichloromethane), mp 70-72° C. 1H NMR (400 MHz, 
DMSO-d6) Ii 8.38 (s, lH), 8.16 (d, 1=8.1 Hz, lH), 8.11 (d, 
1=8.4 Hz, lH), 7.88 (ddd, 1=1.2, 6.9, 8.2 Hz, lH), 7.68 (ddd, 
l=l.3, 6.9, 8.3 Hz, lH), 7.61-7.5 (m, lH), 7.29 (t, 1=8 Hz, 
2H), 3.47 (t, 1=5 Hz, 4H), 2.57 (t, 1=4.7 Hz, 4H), 2.27 (s, 
3H). 13C NMR (101 MHz, DMSO-d6) ll 161.82 (dd, 1=5.3, 
251.1 Hz, 2C), 160.77, 144.84, 136.70, 131.31, 131.15 (t, 
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1=9.2 Hz), 127.19, 126.14, 124.54, 119.27, 112.12 (dd, 
1=3.7, 20.1 Hz, 2C). 107.32, 101.20 (t, 1=19.7 Hz), 95.34 (t, 
1=3 Hz), 81.52, 54.56 (2C), 50.65 (2C), 45.78. HRMS (ESI) 
calcd for C22H20F2N3 [MH+]: 364.1620. Found: 364.1614. 
Anal, Calcd for C22H19F2N3: C, 72.71; H, 5.27; N, 11.56. 5 
Found: C, 72.91; H, 5.12, N, 11.67. 
8-( (2, 6-Difluoropheny l)ethyny 1)-N,N -dimethy 1-1, 6-
naphthyridin-5-amine (Sqq). Yield 76%, Rf=0.29 (1:2 ethyl 
acetate-hexane), mp 149-150° C. 1H NMR (400 MHz, 
DMSO-d6) Ii 9.04 (dd, 1=1.7, 4.2 Hz, lH), 8.59 (dd, 1=1.7, 10 
8.5 Hz, lH), 8.45 (s, lH), 7.57 (dd, 1=4.2, 8.5 Hz, lH), 
7.53-7.46 (m, lH), 7.25 (t, 1=8 Hz, 2H), 3.25 (s, 6H). 13C 
NMR (101 MHz, DMSO-d6) Ii 161.9 (dd, 1=5.3, 250.9 Hz, 
2C), 160.35, 153.88, 152.18, 148.92, 135.3, 130.67 (t, 
1=10.1 Hz), 120.82, 113.48, 111.84 (dd, 1=3.8, 20.1 Hz, 2C), 15 
106.58, 101.86 (t, 1=19.8 Hz), 96.37 (t, 1=3.0 Hz), 79.73, 
42.31 (2C). HRMS (ESI) calcd for C18H14F2N3 [MH+]: 
310.1150. Found: 310.1147.Anal. Calcd forC 18H13F2N3: C, 
69.89; H, 4.24; N, 13.58. Found: C, 70.01; H, 4.44, N, 13.53. 
7-((2,6-Difluorophenyl)ethynyl)quinazoline (5rr). Yield 20 
68%; recrystallized from acetonitrile; mp 166-168° C. 1H 
NMR (400 MHz, DMSO-d6) Ii 9.68 (s, lH), 9.37 (s, lH), 
8.25 (d, 1=8.4 Hz, lH), 8.2 (s, lH), 7.89 (dd, 1=1.6, 8.4 Hz, 
lH), 7.69-7.53 (m, lH), 7.31 (t, 1=8.1 Hz, 2H). 13C NMR 
(101 MHz, DMSO-d6) Ii 162.19 (dd, 1=4.9, 252.6 Hz, 2C), 25 
160.85, 156.02, 148.92, 132.46 (t, 1=10.2 Hz), 130.75, 
130.11, 128.79, 127.1, 124.50, 112.14 (dd, 1=5, 18.6 Hz, 
2C), 100.21 (t, 1=19.7 Hz), 97.51 (t, 1=3 Hz), 79.73. HRMS 
(ESI) calcd for C15H9F2N2 [MH+]: 267.0728. Found: 
267.0710. Anal. Calcd for cl6H8F2N2: C, 72.18; H, 3.03; N, 30 
10.52. Found: C, 71.97; H, 3.22; N, 10.29. 
3,5-Difluoro-4-(phenylethynyl)pyridine (7a). Yield 88%; 
preparative layer chromatography using 1 :20 ethyl acetate-
hexane (Rf=0.48); mp 52-54° C. 1H NMR (400 MHz, 
DMSO-d6) ll 8.67 (s, 2H), 7.69-7.62 (m, 2H), 7.58-7.47 (m, 35 
3H). 13C NMR (101 MHz, DMSO-d6) ll 157.60 (d, 1=264.1 
Hz, 2C), 134.52 (dd, 1=21.8, 4.6 Hz, 2C), 131.87 (2C), 
130.58, 129.09 (2C), 120.20, 108.59 (t, 1=16.5 Hz), 103.10 
(t, 1=2.9 Hz), 73.82. HRMS (ESI) calcd for C13H8F2N 
[MH+]: 216.0619. Found: 216.0619. Anal. Calcd for 40 
C13H7 F2N: C, 72.56; H, 3.28; N, 6.51. Found: C, 72.78; H, 
3.38, N, 6.58. 
4-((3,5-Difluoropyridin-4-yl)ethynyl)aniline (7b ). Yield 
69%; preparative layer chromatography using 1:5 ethyl 
acetate-hexane (Rf=0.3); mp 156-158° C., 1H NMR (400 45 
MHz, DMSO-d6) ll 8.58 (s, 2H), 7.28 (d, 1=8.4 Hz, 2H), 6.59 
(d, 1=8.3 Hz, 2H), 5.91 (s, 2H, NH2). 
13C NMR (101 MHz, 
DMSO-d6) Ii 157.31 (d, 1=262.2 Hz, 2C), 151.19, 134.17 
(dd, 1=21.5, 4.8 Hz, 2C), 133.48 (2C), 113.62 (2C), 109.81 
(t, 1=16.7 Hz), 106.67 (t, 1=2.9 Hz), 105.47, 71.86. HRMS 50 
(ESI) calcd for C13H9F2N2 [MH+]: 231.0728. Found: 
231.0730. Anal. Calcd for C13H8F2N2: C, 67.82; H, 3.50; N, 
12.17. Found: C, 67.64; H, 3.69, N, 12.10. 
4-((3,5-Difluoropyridin-4-yl)ethynyl)-N-methylaniline 
(7c ). Yield 54%; preparative layer chromatography using 1 :5 55 
ethyl acetate-hexane (Rf=0.26); mp 149-151 ° C. 1H NMR 
(400 MHz, DMSO-d6) Ii 8.60 (s, 2H), 7.35 (d, 1=8.6 Hz, 
2H), 6.58 (d, 1=8.6 Hz, 2H), 6.49 (q, 1=5.0 Hz, lH), 2.72 (d, 
1=5.0 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) Ii 157.30 
(d, 1=262.2 Hz, 2C), 151.50, 134.17 (dd, 1=21.6, 4.9 Hz, 60 
2C), 133.41 (2C), 111.54 (2C), 109.80 (t, 1=16.6 Hz), 106.66 
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using 1:5 ethyl acetate-hexane (Rf=0.47); mp 39-140° C. 1H 
NMR (400 MHz, DMSO-d6) Ii 8.60 (s, 2H), 7.43 (d, 1=8.5 
Hz, 2H), 6.74 (d, 1=8.6 Hz, 2H), 2.99 (s, 6H). 13C NMR (101 
MHz, DMSO-d6) Ii 157.32 (d, 1=262.4 Hz, 2C), 151.14, 
134.21 (dd, 1=21.6, 4.8 Hz, 2C), 133.21 (2C), 111.80 (2C), 
109.67 (t, 1=16.7 Hz), 106.17 (t, 1=2.9 Hz), 105.72, 72.48, 
39.59 (2C). HRMS (ESI) calcd for C15H13F2N2 [MH+]: 
259.1041. Found: 259.1041. Anal. Calcd for C15H12F2N2: 
C, 69.76; H, 4.68; N, 10.85. Found: C, 69.50; H, 4.78, N, 
10.78. 
Cell proliferation assay. LSI 74T cells were grown in 
RPMI medium (Mediatech) supplemented with 5% fetal 
bovine serum and 1 % penicillin/streptomycin. For cell pro-
liferation assays, 3xl04 cells/well growing in 12-well plates 
were treated with DMSO or inhibitors. The cell numbers and 
viability were analyzed by Vi-Cell Cell Viability Analyzer 
after 4 days. The IC50 values were calculated with GraphPad 
Prim 5. 
Western blotting. Western blotting was performed as 
described previously. The following antibodies were used: 
anti-c-myc (Epitomics, 1472-1), anti-p21 Wifllc,pI (Cell Sig-
naling, 2947), anti-~-tubulin (DSHB, E7). 
Only the preferred embodiment of the present invention 
and examples of its versatility are shown and described in 
the present disclosure. It is to be understood that the present 
invention is capable of use in various other combinations 
and environments and is capable of changes or modifications 
within the scope of the inventive concept as expressed 
herein. Thus, for example, those skilled in the art will 
recognize, or be able to ascertain, using no more than routine 
experimentation, numerous equivalents to the specific sub-
stances, procedures and arrangements described herein. 
Such equivalents are considered to be within the scope of 
this invention, and are covered by the following claims. 
What is claimed is: 
1. A pharmaceutical composition comprising a compound 
according to the following formula (I): 
(I) 
Ys 
or a pharmaceutically acceptable salt thereof, and a phar-
maceutically acceptable carrier; 
wherein each of X1 through X5 independently repre-
sents H, a lower alkyl, alkoxy, halo, and/or NR1R2; 
wherein n is either 1 or O and when n is 1, each ofY1 
through Y 4 independently represents H, a lower alkyl 
or alkoxy, or NR1R2; 
wherein Heterocycle represents a pyridine; 
wherein Y5 includes two or more halogens which can 
be the same or different; and 
wherein each of R1 and R2 independently represent H 
or a lower alkyl. 
2. The pharmaceutical composition of claim 1, wherein 
Y5 includes at least two fluoro groups. 
(t, 1=2.8 Hz), 105.34, 72.10, 29.16. HRMS (ESI) calcd for 
C14H11F2N2 [MH+]: 245.0885. Found: 245.0885. Anal. 
Calcd for C14H10F2N2: C, 68.85; H, 4.13; N, 11.47, Found: 
C, 68.64; H, 4.40, N, 11.27. 
4-((3,5-Difluoropyridin-4-yl)ethynyl)-N,N-dimethylani-
line (7d). Yield 78%; preparative layer chromatography 
3. The pharmaceutical composition of claim 1, wherein n 
65 is O and at least one of X1 through X5 is NR1 R2. 
4. The pharmaceutical composition of claim 3, wherein 
X3 represents NR1 R2. 
US 10,449,186 B2 
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5. The pharmaceutical composition of claim 3, wherein 
both of R1 and R2 are methyl. 
6. A method of treating cancer, the method comprising 
administering to a patient in need of such treatment an 
effective amount of a compound according to claim 1. 
7. A pharmaceutical composition comprising a compound 
according to the following formula (I): 
24 
(i) a fluoro and chloro, (ii) both fluoro, (iii) both chloro 
groups. 
10. A method of treating cancer, the method comprising 
administering to a patient in need of such treatment an 
5 effective amount of a compound according to claim 7. 
11. The method of claim 10, wherein at least two of X1 
through X5 are halo groups. 
12. The method of claim 11, wherein X 1 through X5 is 
(I) 
10 
either (i) a fluoro and chloro, (ii) both fluoro, or (iii) both 
chloro groups. 
or a pharmaceutically acceptable salt thereof, and a phar-
maceutically acceptable carrier; 
wherein each of X1 through X5 independently repre-
sents H, a lower alkyl, alkoxy, halo, and/or NR1R2 ; 
n is either 1 or O and when n is 1, each ofY 1 through 
Y 4 independently represents H, a lower alkyl or 
alkoxy, or NR1 R2 ; Heterocycle represents a hetero-
cycle ring selected among oxopiperidine, morpho-
line, piperazine, N-methylpiperazine, N-pyrrole, 2,5-
dimethyl-N-pyrrole, quinoline, isoquinoline, indole, 
indazole, and naphthyridine; and Y5 represents one 
13. The method of claim 10, wherein both R1 and R2 are 
lower alkyl groups. 
14. The method of claim 13, wherein either X1 or X5 or 
15 both X1 and X5 are halo groups and X2 through X4 are H or 
a lower alkyl. 
15. The method of claim 10, wherein X1 and/or X5 are 
halo groups, X2 through X4 are H or a lower alkyl, Y3 is 
NR1R2 , and Yi, Y2 , Y4 , and Y5 independently represent Hor 
20 a lower alkyl. 
16. The method of claim 10, wherein X1 and/or X5 are 
fluoro and/or chloro and at least one of R1 or R2 is a lower 
alkyl. 
17. The method of claim 10, wherein n is O and the 
25 heterocycle ring is a lower alkyl substituted or unsubstituted 
N-pyrrole. 
18. The method of claim 10, wherein n is O and the 
heterocycle ring is a lower alkyl substituted or unsubstituted 
isoquinoline. 
or more NR1 R2 , or one or more halogens which can 30 
be the same or different, wherein each of R1 and R2 
independently represent H, or a lower alkyl. 
19. The method of claim 10, wherein the cancer treated is 
selected from the group consisting of colorectal cancer, 
leukemias, breast cancer, ovarian cancer, lung cancer, pros-
tate cancer, and liver cancer. 8. The pharmaceutical composition of claim 7, wherein at 
least two of X1 through X5 is are halo groups. 
9. The pharmaceutical composition of claim 7, wherein 
X1 through X5 is either: 
20. The method of claim 10, wherein the cancer treated is 
35 colorectal cancer. 
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